Ureido-substituted fused heteroaryl compound, preparation method thereof and application thereof in medicine
By developing urea-substituted fused heteroaryl compounds of general formula (I) as TYK2 inhibitors, blocking the IL-12/IL-23 and type I IFN signaling pathways, the problem of the difficulty in inhibiting TYK2-mediated cytokine signaling pathways in the prior art has been solved, and effective treatment of autoimmune diseases and inflammatory diseases has been achieved.
Patent Information
- Application Number
- CN202410567434.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-19
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-12
AI Technical Summary
Existing technologies are unable to effectively inhibit TYK2-mediated cytokine signaling pathways, resulting in limited therapeutic effects for autoimmune and inflammatory diseases.
A urea-substituted fused heteroaryl compound of general formula (I) was developed as a TYK2 inhibitor. It inhibits TYK2 activity by binding to the TYK2 protein target and blocking the IL-12/IL-23 and type I IFN signaling pathways.
This compound can significantly block the IL-12/IL-23 and type I IFN signaling pathways, demonstrating significant efficacy in a variety of experimental autoimmune disease models, including psoriasis, SLE and IBD, with a good risk-benefit ratio.
Smart Images

Figure CN118930547A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure belongs to the field of medicine and relates to a urea-substituted fused heteroaryl compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and use thereof as a therapeutic agent, in particular, use thereof as a TYK2 inhibitor and use thereof in the preparation of a drug for treating and / or preventing diseases or conditions mediated by or dependent on TYK2. Background Art
[0002] Cytokine signaling plays a key role in controlling the growth, differentiation, function, and communication of immune cells. Multiple cytokine signaling pathways are mediated by the actions of receptor-bound Janus kinases (JAKs) and signal transducers and activators of transcription (STATs).
[0003] JAK family members, including JAK1, JAK2, JAK3 and TYK2, are cytokine receptor-associated non-receptor tyrosine protein kinases. After stimulation and oligomerization of these receptors, JAK molecules are activated and phosphorylate receptor tyrosine residues to serve as docking sites for subsequent recruitment and phosphorylation of STAT proteins. In turn, phosphorylated STAT proteins dimerize, translocate to the nucleus and activate transcription of genes that mediate cytokine-induced responses. These cytokine-mediated JAK / STAT pathways are tightly regulated, and dysfunctional JAK / STAT activity has been shown to be a hallmark of many immune and autoimmune diseases, inflammatory diseases, and cell transformation.
[0004] Tyrosine kinase 2 (TYK2) is the first member identified in the JAK family, a component of various cytokine pathways, leading to STAT-dependent gene transcription and specific functional responses of cytokines, including the interleukin 12 / -23 family (IL-12 / IL-23, with a common p40 subunit), the type I interferon (IFN) family, and the IL-6 and IL-10 families. TYK2-mediated cytokine signaling plays a key role in the pathogenesis of autoimmune and inflammatory diseases. Specifically, IL-23 (a heterodimer containing p40 and p19 subunits) is essential for the differentiation and proliferation of T helper cells 17 (Th17), which are key players in several autoimmune diseases (Aggarwal, S et al., "Interleukin-23 promotes a distinct CD4T cell activation state characterized by the production of interleukin-17" J Biol Chem. 2003, 278: 1910-1914). IL-12, which consists of p40 and a unique p35 subunit, plays an important role in regulating Th1 development and IFN-γ secretion by these cells. By mediating Th1 / Th17 responses, IL-12 and IL-23 play an important role in a variety of inflammatory diseases [such as psoriasis (Ps), lupus, inflammatory bowel disease (IBD), multiple sclerosis (MS), rheumatoid arthritis (RA)], etc. For example, in mouse models, it was found that blocking or deleting the common subunit P40 or the common receptor IL23R of IL-12 and IL-23 protected mice from various autoimmune diseases (psoriasis, lupus, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, etc.). In human disease, high levels of IL-12 and IL-23 were observed in the lesional skin of psoriasis patients, and then the levels decreased after various treatments for psoriasis. In addition, monoclonal antibodies that block the common IL-12 / IL-23 subunit p40 (Ustekinumab, Briakinumab, etc.) or the IL-23 specific subunit p19 (Tildrakizumab, Risankizumab, etc.) have been shown to have clinical efficacy in the treatment of psoriasis, Crohn's disease, etc. At the same time, type I IFN family members (IFN-α, -β, -ε, -κ, -ω, etc.) that act through heterodimeric IFN receptors (IFNARs) are important mediators of innate and adaptive immunity, and can also activate multiple elements in the immune response and enhance the expression and release of self-antigens, becoming key players in the expansion of autoimmune diseases.The importance of type I IFN in the pathogenesis of systemic lupus erythematosus (SLE) has been experimentally confirmed. In human SLE patients, elevated serum IFNα levels and increased expression of type I IFN-regulated genes in peripheral blood mononuclear cells (PBMCs) and affected organs have been found in many patients. In addition, other studies have also reported that the activation of type I IFN is closely related to the disease severity of SLE.
[0005] Multiple studies have shown the importance of TYK2 in the pathogenesis of the above autoimmune diseases. For example, rodents with inactivated or chemically inhibited TYK2 in vivo were found to exhibit disease resistance in experimental autoimmune disease models such as psoriasis, multiple sclerosis, and inflammatory bowel disease. Population studies have found that children and adults carrying TYK2 active deletion variants (such as rs12720356 and rs34536443) in the Mexican Mestizo population have reduced SLE incidence. In addition, TYK2 SNP mutations have also been reported to be associated with SLE in Nordic, British, and Chinese Han populations. Genome-wide association studies (GWAS) have found that several active deletion variants of TYK2 are significantly associated with resistance to inflammatory diseases, including multiple sclerosis, psoriasis, Crohn's disease, lupus, and rheumatoid arthritis, further indicating that TYK2 plays an important role in a wide range of autoimmune diseases.
[0006] It can be seen that the development of drugs that inhibit the action of TYK2-mediated cytokine signaling pathways has potential therapeutic benefits for human autoimmune diseases. In fact, the highly selective allosteric TYK2 inhibitor BMS986165 has been shown to effectively block the IL-12 / IL-23 and type I IFN signaling pathways, thereby showing significant efficacy in multiple experimental autoimmune disease models (psoriasis, SLE, and IBD). In addition, the results of a phase 2 clinical trial reported that the drug achieved the primary efficacy endpoint in patients with moderate to severe plaque psoriasis with a good risk-benefit ratio. After taking BMS986165 for 12 weeks, most patients had a decrease in psoriasis area and severity index scores of more than 75% (PASI 75), and some patients had a decrease in PASI scores of more than 90% (PASI 90), further illustrating the effectiveness and potential of the TYK2 target in the treatment of autoimmune diseases.
[0007] Disclosed patent applications for TYK2 inhibitors include WO2014074661A1, WO2020086616A1, WO2020092196A1, WO2020156311A1, WO2019023468A1, WO2020163778A1, WO2020081508A1, WO2021092246A1, WO2021162942A1, and the like. Summary of the invention
[0008] The purpose of the present disclosure is to provide a compound represented by general formula (I), or a pharmaceutically acceptable salt thereof:
[0009] R 0 Selected from
[0010] X 1 , X 2 , X 3 and X 4 One of them is a carbon atom and is connected to NR 7 connected, the rest are the same or different and are each independently N or CR 8 ;
[0011] R A , R B and the carbon atoms connected thereto form a polycyclic cycloalkyl, a polycyclic heterocyclic group, a polycyclic aryl or a polycyclic heteroaryl; the polycyclic cycloalkyl, polycyclic heterocyclic group, polycyclic aryl and polycyclic heteroaryl are each independently and optionally substituted by one or more R 9 replaced by;
[0012] Q and L are the same or different and are each independently selected from a bond, O, (CR g R h ) p 、O(CR g R h ) p , (CR g R h ) p O、NR i 、C(O)NR i NR i C(O) and S(O) q ;
[0013] Ring Cy is a cycloalkyl group or a heterocyclyl group; Ring C is a cycloalkyl group or a heterocyclyl group;
[0014] G 1 Selected from N, NR 10 and CR';
[0015] G 2 N or C; G 3 N or C;
[0016] G 4 is N or CR";
[0017] R 1 is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, and The alkyl, alkoxy, cycloalkylalkyl and heterocyclylalkyl groups are each independently optionally substituted with one or more R 01 replaced by;
[0018] Ring B is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl;
[0019] R 2 , R 2 '、R 4 , R 5 , R 7 , R 10 and R i are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, a cycloalkyl group and a heterocyclic group; the alkyl group, the alkoxy group, the cycloalkyl group and the heterocyclic group are each independently optionally replaced by one or more R 02 replaced by;
[0020] R 3 , R 6 , R' and R" are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a NR 20 R 21 、C(O)NR 20 R 21 、Alkylene NR 20 R 21 、Alkylene C(O)NR 20 R 21 NR 22 C(O)R 23 NR 22 C(O)NR 20 R 21 、C(O)R 23 、C(O)OR 23 、OC(O)R 23 、OC(O)OR 23 、S(O) r R 23 、S(O) r OR 23 、OS(O) r R 23 、S(O) r NR 20 R 21 NR 22 S(O) r R 23 、C(=NR 22 )R 23 、C(=NR 22 )NR20 R 21 、S(=NR 22 )(O)R 23 、P(O)R 23 R 24 , OR 23 , cycloalkyl, heterocyclic, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R 03 replaced by;
[0021] Each R 8 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a NR 20 R 21 、C(O)NR 20 R 21 、Alkylene NR 20 R 21 、Alkylene C(O)NR 20 R 21 NR 22 C(O)R 23 NR 22 C(O)NR 20 R 21 、C(O)R 23 、C(O)OR 23 、OC(O)R 23 、OC(O)OR 23 、S(O) r R 23 、S(O) r OR 23 、OS(O) r R 23 、S(O) r NR 20 R 21 NR 22 S(O) r R 23 、C(=NR 22 )R 23 、C(=NR 22 )NR 20 R 21 、S(=NR 22 )(O)R 23 、P(O)R 23 R 24 , OR 23, cycloalkyl, heterocyclic, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R 03 replaced by;
[0022] Each R e , R f , R g and R h are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a NR 20 R 21 , OR 23 , cycloalkyl, heterocyclic, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R 03 or R e , R f Together they form =O, or R g , R h Together they form = O;
[0023] Each R 9 , R 01 , R 02 and R 03 are the same or different and are each independently selected from a deuterium atom, an oxo group, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a deuterated alkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an alkenyl group, an alkynyl group, ═CR 23 R 24 NR 20 R 21 、C(O)NR 20 R 21 、Alkylene NR 20 R 21 、Alkylene C(O)NR 20 R 21 NR 22 C(O)R 23 NR 22 C(O)NR 20 R 21 、C(O)R 23 、C(O)OR 23 、OC(O)R 23 、OC(O)OR 23 、S(O) r R 23 、S(O) r OR 23 、OS(O) r R23 、S(O) r NR 20 R 21 NR 22 S(O) r R 23 、C(=NR 22 )R 23 、C(=NR 22 )NR 20 R 21 、S(=NR 22 )(O)R 23 、P(O)R 23 R 24 , OR 23 , nitro, cycloalkyl, heterocyclyl, cycloalkyloxy, heterocyclyloxy, aryl, heteroaryl, aryloxy and heteroaryloxy; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, cycloalkyloxy, heterocyclyloxy, aryl, heteroaryl, aryloxy and heteroaryloxy groups are each independently substituted with one or more R*;
[0024] Each R 20 , R 21 , R 22 , R 23 and R 24 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, a hydroxyl group, an alkenyl group, an alkynyl group, NR a R b 、C(O)NR a R b 、Alkylene NR a R b 、Alkylene C(O)NR a R b NR c C(O)R d NR c C(O)NR a R b 、C(O)R d 、C(O)OR d 、OC(O)R d 、OC(O)OR d , OR d , cycloalkyl, heterocyclyl, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently substituted by one or more R*;
[0025] or R 20 , R 21 and the nitrogen atom to which it is attached together form a heterocyclic group, which is optionally substituted by one or more R*;
[0026] Each R a , R b , R c and R d are the same or different and are each independently selected from alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkenyl, alkynyl, amino, NHCH3, N(CH3)2, amide, C(O)NHCH3, C(O)N(CH3)2, acetyl, alkyleneamino, alkyleneamide, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy, heterocyclyloxy, aryl and heteroaryl; or, R a , R b and the nitrogen atom to which it is attached together form a heterocyclic group, wherein the heterocyclic group is substituted by one or more R*;
[0027] each R* is the same or different and is independently selected from a deuterium atom, an oxo group, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an alkenyl group, an alkynyl group, an amino group, NHCH3, N(CH3)2, an amide group, C(O)NHCH3, C(O)N(CH3)2, an acetyl group, an alkyleneamino group, an alkyleneamide group, a nitro group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, a cycloalkyloxy group, a heterocyclyloxy group, an aryl group, and a heteroaryl group;
[0028] Each r and q are the same or different and are each independently 0, 1 or 2;
[0029] m is 0, 1, 2, 3, 4, 5 or 6;
[0030] t is 0, 1, 2, 3, 4, 5, or 6;
[0031] s is 0, 1, 2, 3, 4, 5, or 6; and,
[0032] p is 0, 1, 2, 3, 4, 5 or 6.
[0033] The purpose of the present disclosure is to provide a compound represented by general formula (I), or a pharmaceutically acceptable salt thereof:
[0034]
[0035] in:
[0036] R 0 for
[0037] X 1 , X 2 , X 3 and X 4 One of them is a carbon atom and is connected to NR 7connected, the rest are the same or different and are each independently N or CR 8 ;
[0038] Q and L are the same or different and are each independently selected from a bond, O, (CR g R h ) p 、O(CR g R h ) p , (CR g R h ) p O、NR i 、C(O)NR i NR i C(O) and S(O) q ;
[0039] Ring Cy is a cycloalkyl group or a heterocyclyl group;
[0040] G 1 Selected from N, NR 10 and CR';
[0041] G 2 N or C; G 3 N or C;
[0042] G 4 is N or CR";
[0043] R 1 is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, and The alkyl, alkoxy, cycloalkylalkyl and heterocyclylalkyl groups are each independently optionally substituted with one or more R 01 replaced by;
[0044] Ring B is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl;
[0045] R 2 , R 2 '、R 4 , R 5 , R 7 , R 10 and R i are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, a cycloalkyl group and a heterocyclic group; the alkyl group, the alkoxy group, the cycloalkyl group and the heterocyclic group are each independently optionally replaced by one or more R 02 replaced by;
[0046] R 3 , R 6, R' and R" are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a NR 20 R 21 、C(O)NR 20 R 21 、Alkylene NR 20 R 21 、Alkylene C(O)NR 20 R 21 NR 22 C(O)R 23 NR 22 C(O)NR 20 R 21 、C(O)R 23 、C(O)OR 23 、OC(O)R 23 、OC(O)OR 23 、S(O) r R 23 、S(O) r OR 23 、OS(O) r R 23 、S(O) r NR 20 R 21 NR 22 S(O) r R 23 、C(=NR 22 )R 23 、C(=NR 22 )NR 20 R 21 、S(=NR 22 )(O)R 23 、P(O)R 23 R 24 , OR 23 , cycloalkyl, heterocyclic, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R 03 replaced by;
[0047] Each R 8 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a NR 20 R 21 、C(O)NR 20 R 21 、Alkylene NR 20R 21 、Alkylene C(O)NR 20 R 21 NR 22 C(O)R 23 NR 22 C(O)NR 20 R 21 、C(O)R 23 、C(O)OR 23 、OC(O)R 23 、OC(O)OR 23 、S(O) r R 23 、S(O) r OR 23 、OS(O) r R 23 、S(O) r NR 20 R 21 NR 22 S(O) r R 23 、C(=NR 22 )R 23 、C(=NR 22 )NR 20 R 21 、S(=NR 22 )(O)R 23 、P(O)R 23 R 24 , OR 23 , cycloalkyl, heterocyclic, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R 03 replaced by;
[0048] Each R e , R f , R g and R h are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a NR 20 R 21 , OR 23 , cycloalkyl, heterocyclic, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R 03 or R e , R f Together they form =O, or R g , R hTogether they form = O;
[0049] Each R 9 , R 01 , R 02 and R 03 are the same or different and are each independently selected from a deuterium atom, an oxo group, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a deuterated alkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an alkenyl group, an alkynyl group, NR 20 R 21 、C(O)NR 20 R 21 、Alkylene NR 20 R 21 、Alkylene C(O)NR 20 R 21 NR 22 C(O)R 23 NR 22 C(O)NR 20 R 21 、C(O)R 23 、C(O)OR 23 、OC(O)R 23 、OC(O)OR 23 、S(O) r R 23 、S(O) r OR 23 、OS(O) r R 23 、S(O) r NR 20 R 21 NR 22 S(O) r R 23 、C(=NR 22 )R 23 、C(=NR 22 )NR 20 R 21 、S(=NR 22 )(O)R 23 、P(O)R 23 R 24 , OR 23 , nitro, cycloalkyl, heterocyclyl, cycloalkyloxy, heterocyclyloxy, aryl, heteroaryl, aryloxy and heteroaryloxy; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, cycloalkyloxy, heterocyclyloxy, aryl, heteroaryl, aryloxy and heteroaryloxy groups are each independently substituted with one or more R*;
[0050] Each R 20 , R 21 , R22 , R 23 and R 24 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, a hydroxyl group, an alkenyl group, an alkynyl group, NR a R b 、C(O)NR a R b 、Alkylene NR a R b 、Alkylene C(O)NR a R b NR c C(O)R d NR c C(O)NR a R b 、C(O)R d 、C(O)OR d 、OC(O)R d 、OC(O)OR d , OR d , cycloalkyl, heterocyclyl, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently substituted by one or more R*;
[0051] or R 20 , R 21 and the nitrogen atom to which it is attached together form a heterocyclic group, which is optionally substituted by one or more R*;
[0052] Each R a , R b , R c and R d are the same or different and are each independently selected from alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkenyl, alkynyl, amino, NHCH3, N(CH3)2, amide, C(O)NHCH3, C(O)N(CH3)2, acetyl, alkyleneamino, alkyleneamide, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy, heterocyclyloxy, aryl and heteroaryl; or, R a , R b and the nitrogen atom to which it is attached together form a heterocyclic group, wherein the heterocyclic group is substituted by one or more R*;
[0053] each R* is the same or different and is independently selected from a deuterium atom, an oxo group, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an alkenyl group, an alkynyl group, an amino group, NHCH3, N(CH3)2, an amide group, C(O)NHCH3, C(O)N(CH3)2, an acetyl group, an alkyleneamino group, an alkyleneamide group, a nitro group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, a cycloalkyloxy group, a heterocyclyloxy group, an aryl group, and a heteroaryl group;
[0054] Each r and q are the same or different and are each independently 0, 1 or 2;
[0055] m is 0, 1, 2, 3, 4, 5 or 6;
[0056] t is 0, 1, 2, 3, 4, 5, or 6;
[0057] s is 0, 1, 2, 3, 4, 5, or 6; and,
[0058] p is 0, 1, 2, 3, 4, 5 or 6.
[0059] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R A , R B and the carbon atoms to which they are attached together form a 7- to 12-membered spiro heterocyclic group or a 7- to 12-membered fused heterocyclic group; the 7- to 12-membered spiro heterocyclic group and the 7- to 12-membered fused heterocyclic group are each independently optionally substituted by one or more R 9 In some embodiments, R A , R B and the carbon atoms to which they are attached together form a 7, 8 or 9-membered spiro heterocyclic group or an 8 or 9-membered fused heterocyclic group; the 7, 8 or 9-membered spiro heterocyclic group or the 8 or 9-membered fused heterocyclic group are each independently optionally substituted by one or more R 9 replaced.
[0060] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R 0 for Cycyl, C, Q, L, X 2 , X 3 , X 4 , R e , R f , R 9 , m and t are as defined in the general formula (I);
[0061] In some embodiments, R 0 for R 8a , R 8b and R 8cThe same or different, and each independently is R 8 ; Ring Cy, Ring C, Q, L, R 8 , R 9 , m and t are as defined in the general formula (I);
[0062] In some embodiments, R 0 Selected from v is 0, 1, 2, 3, or 4, R 8b For R 8 ; Q, L and R 8 As defined in general formula (I);
[0063] In some embodiments, R 0 Selected from v is 0, 1, 2, 3, or 4, R 8b For R 8 ; R 8 As defined in general formula (I);
[0064] In some embodiments, R 0 Selected from
[0065] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein: R 0 for Cycyl, Q, L, X 1 , X 2 , X 3 , X 4 , R e , R f , R 9 , m and t are as defined in the general formula (I);
[0066] In some embodiments, R 0 for Cycyl, Q, L, X 1 , X 2 , X 3 , X 4 , R 9 , m and t are as defined in the general formula (I);
[0067] In some embodiments, R 0 for R 8a , R 8b and R 8c are the same or different and are each independently R 8 ; Ring Cy, Q, L, R 8 , R 9, m and t are as defined in the general formula (I);
[0068] In some embodiments, R 0 Selected from R 8a , R 8b and R 8c are the same or different and are each independently R 8 ; R 8 , R 9 , m, p and t are as defined in the general formula (I);
[0069] In some embodiments, R 0 Selected from R 8b For R 8 , R 8 As defined in general formula (I);
[0070] In some embodiments, R 0 Selected from
[0071] In some embodiments, R 0 Selected from In some embodiments, R 0 for R 8b For R 8 , R 8 As defined in Formula (I); in some embodiments, R 0 for In some embodiments, R 0 for
[0072] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein G 4 is N; in some embodiments, G 4 "CR" and "R" are as defined in the general formula (I).
[0073] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein X 1 is a carbon atom and is 7 Connect;X 2 N, X 3 and X 4 All CR 8 , or X 3 N, X 2 and X 4 All CR 8 , or X4 N, X 2 and X 3 All CR 8 , or X 2 , X 3 and X 4 All CR 8 , R 8 As defined in general formula (I);
[0074] In some embodiments, X 1 is a carbon atom and is 7 Connect, X 2 For CH, X 4 For CH, X 3 CR 8 , R 8 As defined in Formula (I); in some embodiments, X 1 With NR 7 Connect, X 2 For CH, X 4 For CH, X 3 CR 8 , R 8 Selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, X 1 With NR 7 Connect, X 2 For CH, X 4 For CH, X 3 is CF;
[0075] In some embodiments, X 2 is a carbon atom and is 7 Connect, X 1 N, X 3 and X 4 All CR 8 , or X 3 N, X 1 and X 4 All CR 8 , or X 4 N, X 1 and X 3 All CR 8 , or X 1 , X 3 and X 4 All CR 8 , R 8 As defined in general formula (I);
[0076] In some embodiments, X 2 is a carbon atom and is 7Connect, X 1 For CH, X 4 For CH, X 3 CR 8 , R 8 As defined in general formula (I).
[0077] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (IV) or a pharmaceutically acceptable salt thereof, wherein for In some embodiments, for In some embodiments, for
[0078] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (IV) or a pharmaceutically acceptable salt thereof, wherein R 1 for Ring B, R 01 and s are as defined in formula (I);
[0079] In some embodiments, R 1 for R 01a is a hydrogen atom or R 01 ; U is selected from CR 1a R 1b , O, S(O) r and NR 1c ; R 1a and R 1b are the same or different and are each independently a hydrogen atom or R 01 ; The condition is that R 1a and R 1b When one of them is an oxo group, the other does not exist; 1c is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, and a heterocyclic group; u is 0, 1, 2, 3, 4, or 5; R 01 and r are as defined in general formula (I);
[0080] In some embodiments, R 1 Selected from R 01a is selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, alkenyl, alkynyl, cycloalkyl and heterocyclyl; U and u are as defined in fragment (b).
[0081] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (II), or a pharmaceutically acceptable salt thereof:
[0082]
[0083] in,
[0084] R 8a , R 8b and R 8c are the same or different and are each independently R 8 ;
[0085] Cy, Q, L, R 2 '、R 01 ,s,R 2 To R 9 , m and t are as defined in the general formula (I).
[0086] In some embodiments of the present disclosure, the compound represented by the general formula (I), (II), (V), (V-1), (V-2), (V-3), (V-4) or a pharmaceutically acceptable salt thereof, wherein ring B is a 3- to 8-membered cycloalkyl or a 3- to 8-membered heterocyclic group; in some embodiments, ring B is a 3- to 6-membered cycloalkyl or a 4- to 7-membered heterocyclic group; in some embodiments, ring B is a 3- to 6-membered cycloalkyl;
[0087] In some embodiments, Ring B is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, pyrrolidinyl, and tetrahydrofuranyl; in some embodiments, Ring B is cyclopropyl or cyclobutyl.
[0088] In some embodiments of the present disclosure, the compound represented by the general formula (I), (II), (V), (V-1), (V-2), (V-3), (V-4) or a pharmaceutically acceptable salt thereof, wherein each R 01 are the same or different and are each independently selected from oxo, halogen, hydroxyl, C 1-6 Alkyl and C 1-6 alkoxy, and / or s is 0, 1 or 2; in some embodiments, each R 01 are the same or different and are each independently selected from oxo, F, hydroxy, methyl and methoxy, and / or s is 0 or 1.
[0089] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein s is 0, 1 or 2; in some embodiments, s is 0; in some embodiments, s is 1.
[0090] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (III), or a pharmaceutically acceptable salt thereof:
[0091]
[0092] Among them, U is selected from CR 1a R 1b , O, S(O) r and NR 1c ;
[0093] R 01a is a hydrogen atom or R 01 ;
[0094] R 1a and R 1b are the same or different and are each independently a hydrogen atom or R 01 ; The condition is that R 1a and R 1b When one of them is an oxo group, the other one does not exist;
[0095] R 1c is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, and a heterocyclic group;
[0096] R 8a , R 8b and R 8c are the same or different and are each independently R 8 ;
[0097] u is 0, 1, 2, 3, 4, or 5;
[0098] Cy, Q, L, R 01 , r, R 2 '、R 2 To R 9 , m and t are as defined in the general formula (I).
[0099] In some embodiments of the present disclosure, the compound represented by the general formula (I), (II), (III) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (III-1), (III-2), (III-3) or (III-4), or a pharmaceutically acceptable salt thereof:
[0100]
[0101]
[0102] in,
[0103] R 01a is selected from the group consisting of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, alkenyl, alkynyl, cycloalkyl and heterocyclyl;
[0104] Cy, Q, L, R 8a , R 8b , R 8c ,U,u,R 2 '、R 2 To R 7 , R 9 , m and t are as defined in the general formula (III).
[0105] In some embodiments of the present disclosure, the compound represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4) or a pharmaceutically acceptable salt thereof, wherein: Selected from In some embodiments, Selected from In some embodiments, for In some embodiments, for
[0106] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4) or their pharmaceutically acceptable salts, wherein ring Cy is a 3- to 12-membered cycloalkyl or a 3- to 12-membered heterocyclyl; in some embodiments, ring Cy is a 3- to 6-membered cycloalkyl or a 3- to 6-membered heterocyclyl; in some embodiments, ring Cy is a 3- to 6-membered cycloalkyl; in some embodiments, ring Cy is a cyclopropyl; in some embodiments, ring Cy is a cyclopropyl or cyclobutyl.
[0107] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IV), or a pharmaceutically acceptable salt thereof:
[0108]
[0109] in,
[0110] Ring C, Q, L, X 2 , X 3 , X 4 , G 1 , G 2 , G 3 , R 1 To R 7 , R 2 '、R 9 and t are as defined in the general formula (I).
[0111] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (IV) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (V), or a pharmaceutically acceptable salt thereof:
[0112]
[0113] in,
[0114] R 8a , R 8b and R 8c are the same or different and are each independently R 8 ;
[0115] Ring B, Ring C, Q, L, R 2 To R 9 , R 2 '、R 01 , s and t are as defined in the general formula (I).
[0116] In some embodiments of the present disclosure, the compound represented by the general formula (I), (IV), (V) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (V-1), (V-2), (V-3) or (V-4), or a pharmaceutically acceptable salt thereof:
[0117]
[0118]
[0119] in,
[0120] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 2 To R 7 , R 2 '、R 01 ,s,R 9 and t are as defined in formula (V).
[0121] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein ring C is a 3- to 6-membered cycloalkyl or a 3- to 6-membered heterocyclic group; in some embodiments, ring C is a 3- to 6-membered cycloalkyl; in some embodiments, ring C is a cyclobutyl or cyclopentyl; in some embodiments, ring C is a cyclobutyl; in some embodiments, ring C is a cyclopentyl.
[0122] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (IV) or a pharmaceutically acceptable salt thereof, wherein Selected from Ring C, Q, L, X 2 , X 3 , X 4 , R 9 and t are as defined in general formula (I);
[0123] In some embodiments, for Further, in some embodiments, Selected from
[0124] Ring C, Q, L, R 8a , R 8b , R 8c , R 9 and t are as defined in formula (V);
[0125] In some embodiments, Selected from
[0126]
[0127] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein Q is a bond or O; in some embodiments, Q is O.
[0128] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein L is selected from a bond, O and CH2O(*), and the * end is connected to the aromatic ring; in some embodiments, L is a bond or O; in some embodiments, L is O.
[0129] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein Q and L are the same or different and are independently selected from a bond, O and CHO; in some embodiments, Q is a bond or O, and / or L is selected from a bond, O and CHO(*), and the * end is connected to the aromatic ring; in some embodiments, Q is O, and / or L is a bond or O; in some embodiments, Q is O, and / or L is O.
[0130] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4) or their pharmaceutically acceptable salts, wherein Q is O, and / or L is O, and / or ring Cy is cyclopropyl, and / or m is 1.
[0131] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein each R 9 are the same or different and are each independently selected from oxo, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, hydroxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, each R 9 are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 Haloalkoxy;
[0132] In some embodiments, each R 9 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl, and / or t is 0, 1 or 2.
[0133] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein t is 0.
[0134] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein each R e and R f are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, R e and R f are all hydrogen atoms; and m is 1.
[0135] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4) or their pharmaceutically acceptable salts, wherein m is 0, 1 or 2; in some embodiments, m is 1; in some embodiments, m is 2; in some embodiments, m is 0.
[0136] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein each R 8 are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, hydroxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, each R 8 are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, each R 8 are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, each R 8 are the same or different and are each independently a hydrogen atom or F; in some embodiments, R 8 is halogen; in some embodiments, R 8 is F; in some embodiments, R 8 A hydrogen atom.
[0137] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein R 8a , R 8b and R 8c are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, hydroxy, cyano, 3- to 6-membered cycloalkyl, and 3- to 6-membered heterocyclyl; in some embodiments, R 8a , R 8b and R 8c are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 8a , R 8b and R 8c are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, R 8a , R 8b and R 8c are the same or different and are each independently a hydrogen atom or F.
[0138] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein R 8b Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, hydroxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, R 8b Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 8b is halogen; in some embodiments, R 8b For F.
[0139] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein R 8a and R 8c are all hydrogen atoms; and / or R 8b It is a halogen.
[0140] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein R 8a and R 8c All are hydrogen atoms.
[0141] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein each R 01 are the same or different and are each independently selected from oxo, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 haloalkoxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, each R 01 are the same or different and are each independently selected from halogen, hydroxyl, C 1-6 Alkyl and C 1-6 alkoxy; in some embodiments, each R 01 are the same or different and are each independently selected from F, hydroxy, methyl and methoxy; in some embodiments, each R 01 are the same or different and are each independently halogen; in some embodiments, R 01 For F.
[0142] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (III) or a pharmaceutically acceptable salt thereof, wherein R 01a For R 01 , R 01 As defined in Formula (I); in some embodiments, R 01a Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6Haloalkyl, C 1-6 Haloalkoxy, hydroxy, C 1-6 hydroxyalkyl, cyano and 3 to 6 membered cycloalkyl; in some embodiments, R 01a Selected from hydrogen atoms, halogens, hydroxyl groups, C 1-6 Alkyl and C 1-6 Alkoxy; in some embodiments, R 01a is halogen; in some embodiments, R 01a For F.
[0143] In some embodiments of the present disclosure, the compound represented by the general formula (I), (III), (III-1), (III-2), (III-3), (III-4) or a pharmaceutically acceptable salt thereof, wherein R 01a Selected from halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, hydroxy, C 1-6 hydroxyalkyl and cyano; in some embodiments, R 01a Selected from halogen, hydroxyl, C 1-6 Alkyl and C 1-6 Alkoxy; in some embodiments, R 01a is halogen; in some embodiments, R 01a For F.
[0144] In some embodiments of the present disclosure, the compound represented by the general formula (I), (III), (III-1), (III-2), (III-3), (III-4) or a pharmaceutically acceptable salt thereof, wherein U is CR 1a R 1b , R 1a and R 1b are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, hydroxy, C 1-6 Hydroxyalkyl and cyano; in some embodiments, U is CH2.
[0145] In some embodiments of the present disclosure, the compound represented by the general formula (I), (III), (III-1), (III-2), (III-3), (III-4) or a pharmaceutically acceptable salt thereof, wherein R 01a is selected from F, hydroxy, methyl and methoxy, and / or U is CH2, and / or u is 0 or 1.
[0146] In some embodiments of the present disclosure, the compound represented by the general formula (I), (III), (III-1), (III-2), (III-3), (III-4) or a pharmaceutically acceptable salt thereof, wherein R 1a and R 1b are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 alkoxy and hydroxy; in some embodiments, R 1a and R 1b are the same or different and are each independently selected from hydrogen, F, methyl, methoxy and hydroxyl; in some embodiments, R 1a and R 1b All are hydrogen atoms.
[0147] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (III), (III-1), (III-2), (III-3), (III-4) or their pharmaceutically acceptable salts, wherein u is 0, 1 or 2; in some embodiments, u is 0; in some embodiments, u is 1.
[0148] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein v is 1 or 2; in some embodiments, v is 1; in some embodiments, v is 2.
[0149] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (IV) or a pharmaceutically acceptable salt thereof, wherein R 1 Selected from
[0150] In some embodiments, R 1 A group selected from Group A, the groups of Group A are defined as follows; in some embodiments, R 1 Selected from In some embodiments, R 1 for
[0151] In some embodiments of the present disclosure, the compound represented by the general formula (I), (II), (V), (V-1), (V-2), (V-3), (V-4) or a pharmaceutically acceptable salt thereof, wherein A group selected from Group A:
[0152]
[0153] In some embodiments, Selected from In some embodiments, for
[0154] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: R 2 A hydrogen atom or C 1-6 Alkyl, and / or R 2 ' is a hydrogen atom or C 1-6 alkyl; in some embodiments, R 2 is a hydrogen atom or a methyl group, and / or R 2 ' is a hydrogen atom or a methyl group; in some embodiments, R 2 is a hydrogen atom, and / or R 2 ' is a hydrogen atom.
[0155] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: R 3 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 haloalkoxy; in some embodiments, R 3 A hydrogen atom.
[0156] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: R 4 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 4 A hydrogen atom.
[0157] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: R 5 Selected from hydrogen atoms, C 1-6alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 5 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 5 C 1-6 alkyl; in some embodiments, R 5 It is methyl.
[0158] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 haloalkoxy; in some embodiments, R 6 A hydrogen atom.
[0159] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: R 2 is a hydrogen atom, and / or R 2 ' is a hydrogen atom, and / or R 3 is a hydrogen atom, and / or R 6 A hydrogen atom.
[0160] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: R 4 is a hydrogen atom, and R 5 C 1-6 alkyl; in some embodiments, R 4 is a hydrogen atom, and R 5 It is methyl.
[0161] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: R7 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 7 A hydrogen atom.
[0162] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: each R 20 , R 21 , R 22 , R 24 , R a , R b and R c are the same or different and are each independently a hydrogen atom or a C 1-6 alkyl; in some embodiments, R 20 , R 21 , R 22 , R 24 , R a , R b and R c All are hydrogen atoms.
[0163] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: each R 23 and R d are the same or different and are each independently a hydrogen atom or a C 1-6 alkyl.
[0164] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: each R g , R h and R i are the same or different and are each independently a hydrogen atom or a C 1-6 alkyl; in some embodiments, R g and R h is a hydrogen atom, R i A hydrogen atom or a methyl group.
[0165] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: p is 1, 2 or 3; in some embodiments, p is 1; in some embodiments, p is 2.
[0166] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: q is 2, and / or r is 2.
[0167] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) or their pharmaceutically acceptable salts, wherein: R 23 and R 24 are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, R 23 and R 24 are the same or different and are each independently a hydrogen atom or F.
[0168] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein for G 4 N; R 1 for Ring B is cyclopropyl or cyclobutyl; each R 01 are the same or different and are each independently selected from oxo, F, hydroxyl, methyl and methoxy, s is 0 or 1; R 2 is a hydrogen atom, R 2 ' is a hydrogen atom, R 3 is a hydrogen atom, R 4 is a hydrogen atom, R 5 C 1-6 Alkyl, R 6 is a hydrogen atom; R 7 is a hydrogen atom; R 0 Selected from
[0169] In some embodiments of the present disclosure, the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof, wherein ring B is cyclopropyl or cyclobutyl; each R 01 are the same or different and are each independently selected from oxo, F, hydroxyl, methyl and methoxy, and / or s is 0 or 1; R 2 is a hydrogen atom, R 2 ' is a hydrogen atom, R 3 is a hydrogen atom, R 4 is a hydrogen atom, R 5 C 1-6 Alkyl, R 6 is a hydrogen atom; R 7 is a hydrogen atom; ring Cy is a cyclopropyl group; Q is O, L is a bond or O; t is 0; m is 0, 1 or 2; R 8a and R 8c are all hydrogen atoms, R 8b It is a halogen.
[0170] In some embodiments of the present disclosure, the compound represented by the general formula (III), (III-1), (III-2), (III-3) or (III-4) or a pharmaceutically acceptable salt thereof, wherein R 01a is selected from F, hydroxy, methyl and methoxy, U is CH2, u is 0 or 1; R 2 is a hydrogen atom, R 2 ' is a hydrogen atom, R 3 is a hydrogen atom, R 4 is a hydrogen atom, R 5 C 1-6 Alkyl, R 6 is a hydrogen atom; R 7 is a hydrogen atom; ring Cy is a cyclopropyl group; Q is O, L is a bond or O; t is 0; m is 0, 1 or 2; R 8a and R 8c are all hydrogen atoms, R 8b It is a halogen.
[0171] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein for G 4 N; R 1 for Ring B is cyclopropyl or cyclobutyl; each R 01 are the same or different and are each independently selected from F, hydroxy, methyl and methoxy, s is 0, 1 or 2; R 2 is a hydrogen atom, R 2 ' is a hydrogen atom, R 3 is a hydrogen atom, R 4 is a hydrogen atom, R 5 is methyl, R6 is a hydrogen atom; R 7 is a hydrogen atom; R 0 Selected from
[0172] In some embodiments of the present disclosure, the compound represented by the general formula (V), (V-1), (V-2), (V-3) or (V-4) or a pharmaceutically acceptable salt thereof, wherein Ring B is cyclopropyl or cyclobutyl; each R 01 are the same or different and are each independently selected from F, hydroxy, methyl and methoxy, s is 0, 1 or 2; R 2 is a hydrogen atom, R 2 ' is a hydrogen atom, R 3 is a hydrogen atom, R 4 is a hydrogen atom, R 5 is methyl, R 6 is a hydrogen atom; R 7 is a hydrogen atom; R 8a and R 8c are all hydrogen atoms, R 8b is halogen; Ring C is cyclobutyl or cyclopentyl, Q is O, L is a bond or O; and t is 0.
[0173] Table A Typical compounds of the present disclosure include, but are not limited to:
[0174]
[0175]
[0176] Another aspect of the present disclosure relates to a compound represented by general formula (IA) or a salt thereof:
[0177]
[0178] Among them, R W is an amino protecting group; preferably PMB;
[0179] G 1 , G 2 , G 3 , G 4 , R 0 To R 3 , R 2 '、R 5 , R 6 and R 7 As defined in general formula (I).
[0180] Another aspect of the present disclosure relates to a compound represented by general formula (IIA) or a salt thereof:
[0181]
[0182] Among them, R W is an amino protecting group; preferably PMB;
[0183] Cy, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (II).
[0184] Another aspect of the present disclosure relates to a compound represented by general formula (IIIA) or a salt thereof:
[0185]
[0186] Among them, R W is an amino protecting group; preferably PMB;
[0187] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (III).
[0188] Another aspect of the present disclosure relates to a compound represented by general formula (III-1A), (III-2A), (III-3A) or (III-4A) or a salt thereof:
[0189]
[0190]
[0191] Among them, R W is an amino protecting group; preferably PMB;
[0192] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 , R 2 '、R 3 , R5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (III-1), (III-2), (III-3) or (III-4).
[0193] Another aspect of the present disclosure relates to a compound represented by general formula (IVA) or a salt thereof:
[0194]
[0195] Among them, R W is an amino protecting group; preferably PMB;
[0196] Ring C, Q, L, X 2 , X 3 , X 4 , G 1 , G 2 , G 3 , R 1 , R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in general formula (IV).
[0197] Another aspect of the present disclosure relates to a compound represented by general formula (VA) or a salt thereof:
[0198]
[0199] Among them, R W is an amino protecting group; preferably PMB;
[0200] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in formula (V).
[0201] Another aspect of the present disclosure relates to a compound represented by general formula (V-1A), (V-2A), (V-3A) or (V-4A) or a salt thereof:
[0202]
[0203] Among them, R W is an amino protecting group; preferably PMB;
[0204] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in formula (V-1), (V-2), (V-3) or (V-4).
[0205] Table B Typical intermediate compounds or their salts disclosed herein include but are not limited to:
[0206]
[0207]
[0208]
[0209] Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:
[0210]
[0211] The compound represented by the general formula (IA) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (I) or its pharmaceutically acceptable salt;
[0212] Among them, R W is an amino protecting group; preferably PMB;
[0213] R 4 is a hydrogen atom;
[0214] G 1 , G 2 , G 3 , G 4 , R 0 To R 3 , R 2 '、R 5 , R 6 and R 7 As defined in general formula (I).
[0215] Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising:
[0216]
[0217] The compound represented by the general formula (IIA) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (II) or its pharmaceutically acceptable salt;
[0218] Among them, R W is an amino protecting group; preferably PMB;
[0219] R 4 is a hydrogen atom;
[0220] Cy, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (II).
[0221] Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (III) or a pharmaceutically acceptable salt thereof, the method comprising:
[0222]
[0223] The compound represented by the general formula (IIIA) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (III) or its pharmaceutically acceptable salt;
[0224] Among them, R W is an amino protecting group; preferably PMB;
[0225] R 4 is a hydrogen atom;
[0226] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (III).
[0227] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (III-1), (III-2), (III-3) or (III-4) or a pharmaceutically acceptable salt thereof, the method comprising:
[0228]
[0229] The compound represented by the general formula (III-1A) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (III-1) or its pharmaceutically acceptable salt;
[0230] The compound represented by the general formula (III-2A) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (III-2) or its pharmaceutically acceptable salt;
[0231] The compound represented by the general formula (III-3A) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (III-3) or its pharmaceutically acceptable salt;
[0232] The compound represented by the general formula (III-4A) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (III-4) or its pharmaceutically acceptable salt;
[0233] Among them, R W is an amino protecting group; preferably PMB;
[0234] R 4 is a hydrogen atom;
[0235] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (III-1), (III-2), (III-3) or (III-4).
[0236] Another aspect of the present disclosure relates to a method for preparing the compounds represented by the above-mentioned general formula (III-1), (III-2), (III-3) and (III-4) or pharmaceutically acceptable salts thereof, the method comprising:
[0237]
[0238] The compound represented by the general formula (III) or its salt is subjected to chiral resolution to obtain the compound represented by the general formula (III-1), (III-2), (III-3) and (III-4) or its pharmaceutically acceptable salt;
[0239] in,
[0240] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 '、R 2 To R 7 , R 9 , m and t are as defined in the general formula (III-1), (III-2), (III-3) or (III-4).
[0241] Another aspect of the present disclosure relates to a method for preparing the compounds represented by the above general formulae (III-1) and (III-4) or pharmaceutically acceptable salts thereof, the method comprising:
[0242] The cis racemic mixture of the compound represented by the general formula (III-1) or its salt is subjected to chiral resolution to obtain the compound represented by the general formula (III-1) and (III-4) or its pharmaceutically acceptable salt;
[0243] in,
[0244] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 '、R 2 To R 7 , R 9 , m and t are as defined in the general formula (III-1) or (III-4).
[0245] Another aspect of the present disclosure relates to a method for preparing the compounds represented by the above general formulae (III-2) and (III-3) or pharmaceutically acceptable salts thereof, the method comprising:
[0246]
[0247] The trans racemic mixture of the compound represented by the general formula (III-2) or its salt is subjected to chiral resolution to obtain the compound represented by the general formula (III-2) and (III-3) or its pharmaceutically acceptable salt;
[0248] in,
[0249] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 '、R2 To R 7 , R 9 , m and t are as defined in the general formula (III-2) or (III-3).
[0250] Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising:
[0251] The compound represented by the general formula (IVA) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (IV) or its pharmaceutically acceptable salt;
[0252] Among them, R W is an amino protecting group; preferably PMB;
[0253] R 4 is a hydrogen atom;
[0254] Ring C, Q, L, X 2 , X 3 , X 4 , G 1 , G 2 , G 3 , R 1 , R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in general formula (IV).
[0255] Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (V) or a pharmaceutically acceptable salt thereof, the method comprising:
[0256]
[0257] The compound represented by the general formula (VA) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (V) or its pharmaceutically acceptable salt;
[0258] Among them, R W is an amino protecting group; preferably PMB;
[0259] R 4 is a hydrogen atom;
[0260] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2'、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in formula (V).
[0261] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (V-1), (V-2), (V-3) or (V-4) or a pharmaceutically acceptable salt thereof, the method comprising:
[0262]
[0263]
[0264] The compound represented by the general formula (V-1A) or a salt thereof undergoes a deprotection reaction to obtain a compound represented by the general formula (V-1) or a pharmaceutically acceptable salt thereof;
[0265] The compound represented by the general formula (V-2A) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (V-2) or its pharmaceutically acceptable salt;
[0266] The compound represented by the general formula (V-3A) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (V-3) or its pharmaceutically acceptable salt;
[0267] The compound represented by the general formula (V-4A) or a salt thereof undergoes a deprotection reaction to obtain a compound represented by the general formula (V-4) or a pharmaceutically acceptable salt thereof;
[0268] Among them, R W is an amino protecting group; preferably PMB;
[0269] R 4 is a hydrogen atom;
[0270] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in formula (V-1), (V-2), (V-3) or (V-4).
[0271] Another aspect of the present disclosure relates to a method for preparing the compounds represented by the above general formulae (V-1), (V-2), (V-3) and (V-4) or pharmaceutically acceptable salts thereof, the method comprising:
[0272]
[0273] The compound represented by the general formula (V) or its salt is subjected to chiral resolution to obtain the compound represented by the general formula (V-1), (V-2), (V-3) and (V-4) or its pharmaceutically acceptable salt;
[0274] in,
[0275] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 '、R 2 To R 7 , R 9 and t are as defined in formula (V-1), (V-2), (V-3) or (V-4).
[0276] Another aspect of the present disclosure relates to a pharmaceutical composition, which contains the compounds of the general formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) and Table A or their pharmaceutically acceptable salts, and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0277] The present disclosure further relates to the use of compounds of formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) and shown in Table A or their pharmaceutically acceptable salts, or pharmaceutical compositions containing the same in the preparation of drugs for inhibiting TYK2 activity.
[0278] The present disclosure further relates to the use of compounds of formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) and shown in Table A or their pharmaceutically acceptable salts, or pharmaceutical compositions comprising the same, in the preparation of TYK2 inhibitors.
[0279] The present disclosure further relates to the use of compounds of formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) and shown in Table A or their pharmaceutically acceptable salts, or pharmaceutical compositions comprising the same, in the preparation of medicaments for treating and / or preventing diseases or conditions mediated by or dependent on TYK2.
[0280] The present disclosure further relates to the use of compounds of formula (I), (II), (III), (III-1), (III-2), (III-3), (III-4), (IV), (V), (V-1), (V-2), (V-3), (V-4) and shown in Table A or their pharmaceutically acceptable salts, or pharmaceutical compositions containing the same in the preparation of drugs for treating and / or preventing proliferative diseases, metabolic diseases, allergic diseases, inflammatory diseases and autoimmune diseases; preferably, the inflammatory diseases or autoimmune diseases The disease is selected from arthritis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus erythematosus, inflammatory bowel disease, psoriasis, psoriatic arthritis, intestinal diseases, Crohn's disease, Sjögren's syndrome, systemic scleroderma, ulcerative colitis, Graves' disease, discoid lupus erythematosus, adult Still's disease, juvenile idiopathic arthritis, gout, gouty arthritis, sepsis, septic shock, shigellosis, pancreatitis, glomerulonephritis, spontaneous nephritis, autoimmune hemolytic anemia, autoimmune Neutropenia, thrombocytopenia, vitiligo, atopic dermatitis, myasthenia gravis, ankylosing spondylitis, pemphigus vulgaris, Goodpasture's syndrome, antiphospholipid syndrome, idiopathic thrombocytopenia, ANCA-associated small vessel vasculitis, pemphigus, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy, dermatomyositis, polymyositis, uveitis, Guillain-Barré syndrome, autoimmune pneumonia, autoimmune thyroiditis, autoimmune inflammatory eye disease, chronic demyelinating polyneuropathy, alopecia areata, and hidradenitis suppurativa ; More preferably, the inflammatory disease or autoimmune disease is selected from rheumatoid arthritis, dermatitis, psoriasis or inflammatory bowel disease; the metabolic disease is preferably diabetes; the proliferative disease is preferably cancer; the cancer is preferably selected from breast cancer, cervical cancer, colorectal cancer, lung cancer, gastric cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, peritoneal tumors, melanoma, glioma, neuroblastoma, head and neck cancer, leukemia, lymphoma and myeloma.
[0281] The active compound may be formulated for administration by any appropriate route, preferably in a unit dosage form, or in a form in which a patient can self-administer a single dose. The unit dosage form of the disclosed compound or composition may be tablets, capsules, cachets, bottled liquids, powders, granules, lozenges, suppositories, reconstituted powders or liquid preparations.
[0282] As a general guide, suitable unit doses may be in the range of 0.1 to 1000 mg.
[0283] The pharmaceutical composition of the present disclosure may contain one or more excipients in addition to the active compound, and the excipients are selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients, etc. Depending on the administration method, the composition may contain 0.1 to 99% by weight of the active compound.
[0284] In some embodiments, the unit dose of the pharmaceutical composition is 0.001 mg-1000 mg.
[0285] In certain embodiments, the pharmaceutical composition contains 0.01-99.99% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution, based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1-99.9% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 1%-99% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 2%-98% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution.
[0286] In certain embodiments, the pharmaceutical composition contains 0.01%-99.99% of a pharmaceutically acceptable excipient based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1%-99.9% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition contains 1%-99% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition contains 2%-98% of a pharmaceutically acceptable excipient.
[0287] The pharmaceutical composition containing the active ingredient may be in a form suitable for oral administration, such as tablets, lozenges, pastilles, water or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Oral compositions may be prepared according to any known method for preparing pharmaceutical compositions in the art, and such compositions may contain one or more ingredients selected from the following: sweeteners, flavoring agents, coloring agents and preservatives to provide a pleasing and palatable pharmaceutical preparation. Tablets contain the active ingredient and non-toxic pharmaceutically acceptable excipients suitable for preparing tablets for mixing. These excipients may be inert excipients, granulating agents, disintegrants, binders and lubricants. These tablets may be uncoated or may be coated by known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained release effect over a longer period of time.
[0288] Oral preparations may also be provided in soft gelatin capsules wherein the active ingredient is mixed with an inert solid diluent or wherein the active ingredient is mixed with a water-soluble carrier or an oily vehicle.
[0289] Aqueous suspensions contain the active substance and excipients suitable for preparing aqueous suspensions for mixing. Such excipients are suspending agents, dispersants or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.
[0290] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil or a mineral oil. The oil suspension may contain a thickener. The above-mentioned sweeteners and flavoring agents may be added to provide a palatable preparation. These compositions may be preserved by adding an antioxidant.
[0291] The pharmaceutical composition of the present disclosure can also be in the form of an oil-in-water emulsion. The oil phase can be a vegetable oil, a mineral oil or a mixture thereof. A suitable emulsifier can be a naturally occurring phospholipid, and the emulsion can also contain a sweetener, a flavoring agent, a preservative and an antioxidant. Such preparations can also contain a demulcent, a preservative, a coloring agent and an antioxidant.
[0292] The pharmaceutical compositions of the present disclosure may be in the form of sterile injectable aqueous solutions. Acceptable vehicles or solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase, and the injection or microemulsion may be injected into the patient's bloodstream by local mass injection. Alternatively, it is preferred that the solution and microemulsion be administered in a manner that maintains a constant circulating concentration of the disclosed compound. To maintain such a constant concentration, a continuous intravenous drug delivery device may be used. An example of such a device is the Deltec CADD-PLUS.TM.5400 intravenous injection pump.
[0293] Pharmaceutical compositions of the present disclosure can be in the form of sterile injection water or oil suspension for intramuscular and subcutaneous administration. The suspension can be prepared with suitable dispersants or wetting agents and suspending agents according to known techniques. Sterile injection preparations can also be sterile injection solutions or suspensions prepared in parenteral acceptable nontoxic diluents or solvents. In addition, sterile fixed oils can be conveniently used as solvents or suspension media. For this purpose, any blended fixed oils can be used. In addition, fatty acids can also be used to prepare injections.
[0294] The disclosed compounds may be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and will therefore melt in the rectum to release the drug.
[0295] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to the following factors: the activity of the specific compound used, the age of the patient, the weight of the patient, the health status of the patient, the behavior of the patient, the diet of the patient, the time of administration, the mode of administration, the rate of excretion, the combination of drugs, the severity of the disease, etc.; in addition, the best treatment method such as the mode of treatment, the daily dosage of the compound or the type of pharmaceutically acceptable salt can be verified according to traditional treatment regimens.
[0296] Terminology
[0297] Unless stated otherwise, the terms used in the specification and claims have the following meanings.
[0298] The term "alkyl" refers to a saturated straight-chain or branched aliphatic hydrocarbon group having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., C 1-20 The alkyl group is preferably an alkyl group having 1 to 12 carbon atoms (i.e., C 1-10 Alkyl), preferably an alkyl group having 1 to 6 carbon atoms (i.e., C 1-6Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2 ,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. The alkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituent is preferably selected from one or more of a D atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.
[0299] The term "alkylene" refers to a divalent alkyl group, wherein alkyl is as defined above, having from 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., C 1-20 The alkylene group is preferably an alkylene group having 1 to 10 carbon atoms (i.e., C 1-10 Alkylene), preferably an alkylene group having 1 to 8 carbon atoms (i.e., C 1-8 alkylene), more preferably an alkylene group having 2 to 7 carbon atoms (i.e., C 2-7 alkylene) or an alkylene group having 1, 2 or 3 carbon atoms (i.e., C 1-6Alkylene). Non-limiting examples include: -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH(CH2CH3)-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, etc. Alkylene can be substituted or unsubstituted, and when substituted, it can be substituted at any available point of attachment, and the substituent is preferably selected from one or more of D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0300] The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein the alkyl group is as defined above and has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkenyl group is preferably an alkenyl group having 2 to 6 carbon atoms (i.e., C 2-6 Alkenyl). Non-limiting examples include: vinyl, propenyl, isopropenyl, butenyl, etc. Alkenyl can be substituted or unsubstituted, and when substituted, it can be substituted at any available point of attachment, and the substituent is preferably selected from one or more of D atoms, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0301] The term "alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond in the molecule, wherein alkyl is as defined above and has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkynyl group is preferably an alkynyl group having 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl). Non-limiting examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Alkynyl can be substituted or unsubstituted, and when substituted, it can be substituted at any available point of attachment, and the substituent is preferably selected from one or more of D atoms, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0302] The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples include: methoxy, ethoxy, propoxy and butoxy, etc. Alkoxy can be substituted or unsubstituted, and when substituted, it can be substituted at any usable point of attachment, and the substituent is preferably selected from one or more of D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0303] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic all-carbon ring (i.e., monocyclic cycloalkyl) or polycyclic ring system (i.e., polycyclic cycloalkyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., 3 to 20-membered cycloalkyl). The cycloalkyl group is preferably a cycloalkyl group having 3 to 12 ring atoms (i.e., 3 to 12-membered cycloalkyl), more preferably a cycloalkyl group having 3 to 8 ring atoms (i.e., 3 to 8-membered cycloalkyl), most preferably a cycloalkyl group having 3 to 6 ring atoms (i.e., 3 to 6-membered cycloalkyl), a cycloalkyl group having 4 to 7 ring atoms (i.e., 4 to 7-membered cycloalkyl) or a cycloalkyl group having 5 or 6 ring atoms (i.e., 5 or 6-membered cycloalkyl); most preferably a cycloalkyl group having 5 or 6 ring atoms.
[0304] Non-limiting examples of the monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl and cyclooctyl.
[0305] The polycyclic cycloalkyl group includes: spirocycloalkyl group, fused cycloalkyl group and bridged cycloalkyl group.
[0306] The term "spirocycloalkyl" refers to a polycyclic system in which one carbon atom (called spiro atom) is shared between the rings, and the rings may contain one or more double bonds, or the rings may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but not including -OO-, -OS- or -SS-), provided that at least one all-carbon ring is contained and the connection point is on the all-carbon ring, and it has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., 5 to 20-membered spirocycloalkyl). The spirocycloalkyl preferably has 6 to 14 ring atoms (i.e., 6 to 14-membered spirocycloalkyl), and more preferably has 7 to 10 ring atoms (i.e., 7 to 10-membered spirocycloalkyl). The spirocycloalkyl includes monospirocycloalkyl and polyspirocycloalkyl (such as bispirocycloalkyl, etc.), preferably monospirocycloalkyl or bispirocycloalkyl, more preferably 3-yuan / 4-yuan, 3-yuan / 5-yuan, 3-yuan / 6-yuan, 4-yuan / 4-yuan, 4-yuan / 5-yuan, 4-yuan / 6-yuan, 5-yuan / 3-yuan, 5-yuan / 4-yuan, 5-yuan / 5-yuan, 5-yuan / 6-yuan, 5-yuan / 7-yuan, 6-yuan / 3-yuan, 6-yuan / 4-yuan, 6-yuan / 5-yuan, 6-yuan / 6-yuan, 6-yuan / 7-yuan, 7-yuan / 5-yuan or 7-yuan / 6-yuan monospirocycloalkyl. Non-limiting examples include:
[0307] Its connection point can be at any position;
[0308] wait.
[0309] The term "fused cycloalkyl" refers to a polycyclic system in which two adjacent carbon atoms are shared between the rings, which is a monocyclic cycloalkyl fused to one or more monocyclic cycloalkyls, or a monocyclic cycloalkyl fused to one or more heterocyclyls, aryls or heteroaryls, wherein the point of attachment is on the monocyclic cycloalkyl, which may contain one or more double bonds within the ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., 5 to 20-membered fused cycloalkyl). The fused cycloalkyl preferably has 6 to 14 ring atoms (i.e., 6 to 14-membered fused cycloalkyl), and more preferably has 7 to 10 ring atoms (i.e., 7 to 10-membered fused cycloalkyl). The fused cycloalkyl includes bicyclic fused cycloalkyl and polycyclic fused cycloalkyl (such as tricyclic fused cycloalkyl, tetracyclic fused cycloalkyl, etc.), preferably bicyclic fused cycloalkyl or tricyclic fused cycloalkyl, more preferably 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan bicyclic fused cycloalkyl. Non-limiting examples include:
[0310] Its connection point can be at any position;
[0311]
[0312] wait.
[0313] The term "bridged cycloalkyl" refers to a full carbon polycyclic system that shares two carbon atoms that are not directly connected between the rings, which may contain one or more double bonds in the ring and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., 5 to 20-membered bridged cycloalkyl). The bridged cycloalkyl preferably has a bridged cycloalkyl of 6 to 14 carbon atoms (i.e., 6 to 14-membered bridged cycloalkyl), and more preferably has a bridged cycloalkyl of 7 to 10 carbon atoms (i.e., 7 to 10-membered bridged cycloalkyl). The bridged cycloalkyl includes bicyclic bridged cycloalkyl and polycyclic bridged cycloalkyl (e.g., tricyclic bridged cycloalkyl, tetracyclic bridged cycloalkyl, etc.), preferably bicyclic bridged cycloalkyl or tricyclic bridged cycloalkyl. Non-limiting examples include:
[0314] Its connection point can be at any position.
[0315] The cycloalkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0316] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic heterocycle (i.e., a monocyclic heterocyclyl) or a polycyclic heterocyclic ring system (i.e., a polycyclic heterocyclyl), which contains at least one (e.g., 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxoed, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS- or -SS-) in the ring, and has 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 3- to 20-membered heterocyclyl). The heterocyclic group is preferably a heterocyclic group having 3 to 12 ring atoms (i.e., a 3- to 12-membered heterocyclic group); further preferably a heterocyclic group having 3 to 8 ring atoms (i.e., a 3- to 8-membered heterocyclic group); more preferably a heterocyclic group having 3 to 6 ring atoms (i.e., a 3- to 6-membered heterocyclic group), a heterocyclic group having 4 to 7 ring atoms (i.e., a 4- to 7-membered heterocyclic group) or a heterocyclic group having 5 or 6 ring atoms (i.e., a 5- or 6-membered heterocyclic group); and most preferably a heterocyclic group having 5 or 6 ring atoms.
[0317] Non-limiting examples of the monocyclic heterocyclic group include pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, azetidinyl, morpholinyl, thiomorpholinyl and homopiperazinyl.
[0318] The polycyclic heterocyclic group includes a spiro heterocyclic group, a fused heterocyclic group and a bridged heterocyclic group.
[0319] "Nitrogen-containing heterocyclic group" refers to a heterocyclic group containing at least one (e.g., 1, 2, 3 or 4) nitrogen atom in the ring, and the heterocyclic group is as defined above. It is preferably a 3- to 10-membered nitrogen-containing heterocyclic group, more preferably a 4- to 7-membered nitrogen-containing heterocyclic group, and most preferably a 5- or 6-membered nitrogen-containing heterocyclic group.
[0320] The term "spiroheterocyclyl" refers to a polycyclic heterocyclic ring system in which the rings share one atom (called a spiro atom), which may contain one or more double bonds in the ring and at least one (e.g., 1, 2, 3 or 4) heteroatom selected from nitrogen, oxygen and sulfur in the ring (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS- or -SS-), provided that it contains at least one monocyclic heterocyclic group and the point of attachment is on the monocyclic heterocyclic group, which has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 5- to 20-membered spiroheterocyclyl). The spiro heterocyclic group preferably has a spiro heterocyclic group of 6 to 14 ring atoms (i.e., a 6 to 14-membered spiro heterocyclic group), and more preferably has a spiro heterocyclic group of 7 to 11 ring atoms (i.e., a 7 to 11-membered spiro heterocyclic group). The spiro heterocyclic group includes a monospiro heterocyclic group and a polyspiro heterocyclic group (such as a bispiro heterocyclic group, etc.), preferably a monospiro heterocyclic group or a bispiro heterocyclic group, more preferably a 3-yuan / 4-yuan, 3-yuan / 5-yuan, 3-yuan / 6-yuan, 4-yuan / 4-yuan, 4-yuan / 5-yuan, 4-yuan / 6-yuan, 5-yuan / 3-yuan, 5-yuan / 4-yuan, 5-yuan / 5-yuan, 5-yuan / 6-yuan, 5-yuan / 7-yuan, 6-yuan / 3-yuan, 6-yuan / 4-yuan, 6-yuan / 5-yuan, 6-yuan / 6-yuan, 6-yuan / 7-yuan, 7-yuan / 5-yuan or 7-yuan / 6-yuan monospiro heterocyclic group. Non-limiting examples include:
[0321]
[0322] wait.
[0323] The term "fused heterocyclyl" refers to a polycyclic heterocyclic ring system which shares two adjacent atoms between the rings, which may contain one or more double bonds within the ring, and which contains at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur within the ring (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS-, or -SS-), which is a monocyclic heterocyclyl fused to one or more monocyclic heterocyclyls, or a monocyclic heterocyclyl fused to one or more of cycloalkyl, aryl, or heteroaryl, wherein the point of attachment is on the monocyclic heterocyclyl, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused heterocyclyl). The fused heterocyclic group preferably has a fused heterocyclic group of 6 to 14 ring atoms (i.e., a 6 to 14-membered fused heterocyclic group), and more preferably has a fused heterocyclic group of 7 to 10 ring atoms (i.e., a 7 to 10-membered fused heterocyclic group). The fused heterocyclic group includes bicyclic and polycyclic fused heterocyclic groups (such as tricyclic fused heterocyclic groups, tetracyclic fused heterocyclic groups, etc.), preferably a bicyclic fused heterocyclic group or a tricyclic fused heterocyclic group, more preferably a 3-yuan / 4-yuan, 3-yuan / 5-yuan, 3-yuan / 6-yuan, 4-yuan / 4-yuan, 4-yuan / 5-yuan, 4-yuan / 6-yuan, 5-yuan / 3-yuan, 5-yuan / 4-yuan, 5-yuan / 5-yuan, 5-yuan / 6-yuan, 5-yuan / 7-yuan, 6-yuan / 3-yuan, 6-yuan / 4-yuan, 6-yuan / 5-yuan, 6-yuan / 6-yuan, 6-yuan / 7-yuan, 7-yuan / 5-yuan or 7-yuan / 6-yuan bicyclic fused heterocyclic group. Non-limiting examples include:
[0324]
[0325] wait.
[0326] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic ring system that shares two atoms that are not directly connected between the rings, which may contain one or more double bonds in the ring, and which contains at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur in the ring (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but does not include -OO-, -OS-, or -SS-), and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., 5 to 20-membered bridged heterocyclic groups). The bridged heterocyclic group is preferably a bridged heterocyclic group having 6 to 14 ring atoms (i.e., 6 to 14-membered bridged heterocyclic groups), and more preferably a bridged heterocyclic group having 7 to 10 ring atoms (i.e., 7 to 10-membered bridged heterocyclic groups). According to the number of constituent rings, it can be divided into bicyclic bridged heterocyclic groups and polycyclic bridged heterocyclic groups (such as tricyclic bridged heterocyclic groups, tetracyclic bridged heterocyclic groups, etc.), preferably bicyclic bridged heterocyclic groups or tricyclic bridged heterocyclic groups. Non-limiting examples include:
[0327] wait.
[0328] The heterocyclic group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic groupoxy, hydroxyl, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclic group, aryl and heteroaryl.
[0329] The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., monocyclic aromatic group) or a polycyclic aromatic ring system (i.e., polycyclic aromatic group) having a conjugated π electron system, which has 6 to 20 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., 6 to 20-membered aromatic group). The aromatic group preferably has 6 to 14 ring atoms (i.e., 6 to 14-membered aromatic group), and more preferably has 6 to 10 ring atoms (i.e., 6 to 10-membered aromatic group). The monocyclic aromatic group is, for example, phenyl. Non-limiting examples of the polycyclic aromatic group include: naphthyl, anthracenyl, phenanthrenyl, etc. The polycyclic aromatic group also includes a phenyl group fused to one or more heterocyclic groups or cycloalkyl groups, or a naphthyl group fused to one or more heterocyclic groups or cycloalkyl groups, wherein the point of attachment is on the phenyl group or naphthyl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic aromatic ring system, non-limiting examples include:
[0330]
[0331] wait.
[0332] The aryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0333] The term "heteroaryl" refers to a monocyclic heteroaromatic ring (i.e., a monocyclic heteroaryl) or a polycyclic heteroaromatic ring system (i.e., a polycyclic heteroaryl) having a conjugated π electron system, which contains at least one (e.g., 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but does not include -OO-, -OS- or -SS-) in the ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 5- to 20-membered heteroaryl). The heteroaryl group is preferably a heteroaryl group having 5 to 14 ring atoms (i.e. a 5- to 14-membered heteroaryl group), more preferably a heteroaryl group having 5 to 10 ring atoms (i.e. a 5- to 10-membered heteroaryl group), and most preferably a heteroaryl group having 5 or 6 ring atoms (i.e. a 5- or 6-membered heteroaryl group).
[0334] The monocyclic heteroaryl group includes, but is not limited to, furanyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridyl, pyrimidinyl, pyridonyl, N-alkylpyridone (e.g. etc.), pyrazinyl, pyridazinyl, etc.
[0335] The polycyclic heteroaryl, non-limiting examples include: indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophenyl, quinazolinyl, benzothiazolyl, carbazolyl, etc. The polycyclic heteroaryl also includes a monocyclic heteroaryl fused with one or more aromatic groups, wherein the connection point is on the aromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. The polycyclic heteroaryl also includes a monocyclic heteroaryl fused with one or more cycloalkyl or heterocyclic groups, wherein the connection point is on the monocyclic heteroaromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. Non-limiting examples include:
[0336]
[0337] wait.
[0338] The heteroaryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0339] The term "cycloalkyloxy" refers to an -O-cycloalkyl group, wherein cycloalkyl is as defined above.
[0340] The term "heterocyclyloxy" refers to an -O-heterocyclyl group wherein the heterocyclyl group is as defined above.
[0341] The term "aryloxy" refers to an -O-aryl group in which aryl is as defined above.
[0342] The term "heteroaryloxy" refers to an -O-heteroaryl group wherein heteroaryl is as defined above.
[0343] The term "cycloalkylalkyl" refers to an alkyl group substituted with one or more cycloalkyl groups, wherein cycloalkyl and alkyl are as defined above.
[0344] The term "heterocyclylalkyl" refers to an alkyl group substituted by one or more heterocyclyl groups, wherein heterocyclyl and alkyl are as defined above.
[0345] The term "arylalkyl" refers to an alkyl group substituted with one or more aryl groups, wherein aryl and alkyl are as defined above.
[0346] The term "heteroarylalkyl" refers to an alkyl group substituted with one or more heteroaryl groups, wherein heteroaryl and alkyl are as defined above.
[0347] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0348] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
[0349] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
[0350] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
[0351] The term "hydroxyalkoxy" refers to an alkoxy group substituted with one or more hydroxy groups, wherein alkoxy is as defined above.
[0352] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0353] The term "hydroxy" refers to -OH.
[0354] The term "amino" refers to -NH2.
[0355] The term "cyano" refers to -CN.
[0356] The term "nitro" refers to -NO2.
[0357] The term "oxo" or "oxo" refers to "=0".
[0358] The term "carbonyl" refers to C=O.
[0359] TBS refers to tert-butyldimethylsilyl.
[0360] The term "amido" refers to -CONH2.
[0361] The term "acetyl" refers to C(O)CH3.
[0362] The term "alkyleneamino" refers to an -alkylene-amino group wherein alkylene and amino are as defined above.
[0363] The term "alkyleneamido" refers to an -alkylene-amide group in which the alkylene and amide groups are as defined above.
[0364] The term "amino protecting group" refers to a group that is easily removed and introduced on the amino group in order to keep the amino group unchanged when other parts of the molecule react. Non-limiting examples include: (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), methyloxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl (Teoc), methoxycarbonyl, ethoxycarbonyl, phthaloyl (Pht), p-toluenesulfonyl (Tos), trifluoroacetyl (Tfa), trityl (Trt), 2,4-dimethoxybenzyl (DMB), acetyl, benzyl, allyl, p-methoxybenzyl (PMB), etc.
[0365] The disclosed compounds may exist in specific stereoisomeric forms. The term "stereoisomer" refers to isomers with identical structures but different arrangements of atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (such as racemates, mixtures of diastereomers). Substituents in the disclosed compounds may have additional asymmetric atoms. All of these stereoisomers and their mixtures are included within the scope of the present disclosure. Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers and (D)- and (L)-isomers may be prepared by chiral synthesis, chiral reagents or other conventional techniques. An isomer of a compound disclosed herein can be prepared by asymmetric synthesis or chiral auxiliary, or, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereoisomer salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are separated by conventional methods known in the art to obtain pure isomers. In addition, the separation of enantiomers and diastereoisomers is usually completed by chromatography.
[0366] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if there are chiral isomers in the chemical structure, the bond Can be or or include both and For all carbon-carbon double bonds, even if only one configuration is named, both the Z and E configurations are included.
[0367] In the chemical structure of the compounds disclosed herein, rac is the abbreviation of racemate (also known as raceme), which refers to an equimolar mixture of a pair of enantiomers. For example, when the compound has only one chiral center, rac refers to an equimolar mixture of (R) configuration and (S) configuration; when the compound has two chiral centers, rac refers to an equimolar mixture of (R,R) configuration and (S,S) configuration; or an equimolar mixture of (R,S) configuration and (S,R) configuration. Specifically, rac-(1R,2R) means that the compound is a racemate, which is an equimolar mixture of (1R,2R) configuration and (1S,2S) configuration.
[0368] The compounds of the present disclosure may exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to a structural isomer that exists in equilibrium and is easily converted from one isomeric form to another isomeric form. It includes all possible tautomers, i.e., in the form of a single isomer or in the form of a mixture of any proportions of the tautomers. Non-limiting examples include: keto-enol, imine-enamine, lactam-lactim, etc. Examples of lactam-lactim equilibrium are shown below:
[0369]
[0370] For example, when referring to pyrazolyl, it is understood to include either or a mixture of two tautomers of the following two structures:
[0371]
[0372] All tautomeric forms are within the scope of the present disclosure, and the naming of compounds does not exclude any tautomer.
[0373] The compounds of the present disclosure include all suitable isotopic derivatives of the compounds thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, for example, respectively. 2 H (deuterium, D), 3 H (tritium, T),11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 32 p. 33 p. 33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 125 I. 129 I and 131 I, etc., preferably deuterium.
[0374] Compared with non-deuterated drugs, deuterated drugs have the advantages of reducing toxic side effects, increasing drug stability, enhancing therapeutic effects, and extending drug biological half-life. All isotopic composition changes of the compounds disclosed herein, whether radioactive or not, are included in the scope of the present disclosure. Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom, wherein the replacement of deuterium can be partial or complete, and partial deuterium replacement means that at least one hydrogen is replaced by at least one deuterium.
[0375] When a position is specifically designated as deuterium, D, the position is understood to have an abundance of deuterium (ie, at least 15% deuterium incorporation) that is at least 1000 times greater than the natural abundance of deuterium, which is 0.015%. Examples of compounds having a greater than natural abundance of deuterium may be at least 1000 times more abundant in deuterium (i.e., at least 15% deuterium incorporation), at least 2000 times more abundant in deuterium (i.e., at least 30% deuterium incorporation), at least 3000 times more abundant in deuterium (i.e., at least 45% deuterium incorporation), at least 3340 times more abundant in deuterium (i.e., at least 50.1% deuterium incorporation), at least 3500 times more abundant in deuterium (i.e., at least 52.5% deuterium incorporation), at least 4000 times more abundant in deuterium (i.e., at least 60% deuterium incorporation), at least 4500 times more abundant in deuterium (i.e., at least 67.5% deuterium incorporation), at least 5000 times more abundant in deuterium (i.e., at least 65.6% deuterium incorporation), at least 5000 times more abundant in deuterium (i.e., at least 60% deuterium incorporation), at least 5000 times more abundant in deuterium (i.e., at least 67.5% deuterium incorporation), at least 5000 times more abundant in deuterium (i.e., at least 60 ... deuterium is incorporated at least 5000 times more abundant in deuterium (i.e., at least 75% deuterium incorporation), at least 5500 times more abundant in deuterium (i.e., at least 82.5% deuterium incorporation), at least 6000 times more abundant in deuterium (i.e., at least 90% deuterium incorporation), at least 6333.3 times more abundant in deuterium (i.e., at least 95% deuterium incorporation), at least 6466.7 times more abundant in deuterium (i.e., at least 97% deuterium incorporation), at least 6600 times more abundant in deuterium (i.e., at least 99% deuterium incorporation), at least 6633.3 times more abundant in deuterium (i.e., at least 99.5% deuterium incorporation), or more.
[0376] "Optional" or "optionally" means that the event or environment described later may but need not occur, and includes both the occurrence and non-occurrence of the event or environment. For example, "C 1-6 The term "alkyl group" includes the case where the alkyl group is substituted by halogen or cyano and the case where the alkyl group is not substituted by halogen or cyano.
[0377] "Substitution" or "substituted" refers to one or more hydrogen atoms in a group, preferably 1, 2 or 3, more preferably 1 to 3 hydrogen atoms, which are independently replaced by a corresponding number of substituents. Those skilled in the art can determine possible or impossible substitutions (by experiment or theory) without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated bond (such as an alkene).
[0378] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their pharmaceutically acceptable salts and other chemical components, as well as other components such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredients, and thus exert biological activity.
[0379] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present disclosure, which may be selected from inorganic or organic salts. Such salts are safe and effective when used in mammals and have the desired biological activity. They may be prepared separately during the final isolation and purification of the compound, or by reacting a suitable group with a suitable base or acid. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include inorganic acids and organic acids.
[0380] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with patient tissues without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio, and effective for the intended use.
[0381] As used herein, the singular form of "a," "an," and "the" include plural references and vice versa unless the context clearly dictates otherwise.
[0382] When the term "about" is applied to a parameter such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and sometimes more preferably within ±5%. As will be understood by those skilled in the art, when a parameter is not critical, numbers are generally given only for illustrative purposes and not for limitation.
[0383] Synthesis method of the disclosed compound
[0384] In order to achieve the purpose of this disclosure, this disclosure adopts the following technical solutions:
[0385] Solution 1
[0386] The method for preparing the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0387]
[0388] The compound represented by the general formula (IA) or its salt undergoes a deprotection reaction under acidic conditions to obtain the compound represented by the general formula (I) or its pharmaceutically acceptable salt;
[0389] Among them, R W is an amino protecting group, preferably PMB;
[0390] R 4 is a hydrogen atom;
[0391] G 1 , G 2 , G 3 , G 4 , R 0 To R 3 , R 2 '、R 5 , R 6 and R 7 As defined in general formula (I).
[0392] Solution 2
[0393] The method for preparing the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0394]
[0395] The compound represented by the general formula (IIA) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof;
[0396] Among them, R W is an amino protecting group, preferably PMB;
[0397] R 4 is a hydrogen atom;
[0398] Cy, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R6 , R 7 , R 9 , m and t are as defined in the general formula (II).
[0399] Option 3
[0400] The method for preparing the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0401]
[0402] The compound represented by the general formula (IIIA) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof;
[0403] Among them, R W is an amino protecting group, preferably PMB;
[0404] R 4 is a hydrogen atom;
[0405] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (III).
[0406] Option 4
[0407] The method for preparing the compound represented by the general formula (III-1) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0408] The compound represented by the general formula (III-1A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (III-1) or a pharmaceutically acceptable salt thereof;
[0409] Among them, R W is an amino protecting group, preferably PMB;
[0410] R 4 is a hydrogen atom;
[0411] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (III-1).
[0412] Option 5
[0413] The method for preparing the compound represented by the general formula (III-2) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0414] The compound represented by the general formula (III-2A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (III-2) or a pharmaceutically acceptable salt thereof;
[0415] Among them, R W is an amino protecting group, preferably PMB;
[0416] R 4 is a hydrogen atom;
[0417] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (III-2).
[0418] Option 6
[0419] The method for preparing the compound represented by the general formula (III-3) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0420] The compound represented by the general formula (III-3A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (III-3) or a pharmaceutically acceptable salt thereof;
[0421] Among them, R W is an amino protecting group, preferably PMB;
[0422] R 4 is a hydrogen atom;
[0423] Cy, Q, L, R 8a , R8b , R 8c , R 01a ,U,u,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (III-3).
[0424] Option 7
[0425] The method for preparing the compound represented by the general formula (III-4) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0426] The compound represented by the general formula (III-4A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (III-4) or a pharmaceutically acceptable salt thereof;
[0427] Among them, R W is an amino protecting group, preferably PMB;
[0428] R 4 is a hydrogen atom;
[0429] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 , m and t are as defined in the general formula (III-4).
[0430] Option 8
[0431] The present invention discloses a method for preparing a compound represented by general formula (III-1), (III-2), (III-3) and (III-4) or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0432]
[0433] The compound represented by the general formula (III-1) or its salt is subjected to chiral resolution to obtain the compound represented by the general formula (III-1), (III-2), (III-3) and (III-4) or its pharmaceutically acceptable salt;
[0434] in,
[0435] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 '、R 2 To R 7 , R 9 , m and t are as defined in the general formula (III-1), (III-2), (III-3) or (III-4).
[0436] Plan 8-1
[0437] The present invention discloses a method for preparing a compound represented by general formula (III-1) and (III-4) or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0438]
[0439] The cis racemic mixture of the compound represented by the general formula (III-1) or its salt is subjected to chiral resolution to obtain the compound represented by the general formula (III-1) and (III-4) or its pharmaceutically acceptable salt;
[0440] in,
[0441] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R 2 '、R 2 To R 7 , R 9 , m and t are as defined in the general formula (III-1) or (III-4).
[0442] Plan 8-2
[0443] The present invention discloses a method for preparing a compound represented by general formula (III-2) and (III-3) or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0444]
[0445] The trans racemic mixture of the compound represented by the general formula (III-2) or its salt is subjected to chiral resolution to obtain the compound represented by the general formula (III-2) and (III-3) or its pharmaceutically acceptable salt;
[0446] in,
[0447] Cy, Q, L, R 8a , R 8b , R 8c , R 01a ,U,u,R2 '、R 2 To R 7 , R 9 , m and t are as defined in the general formula (III-2) or (III-3).
[0448] Option 9
[0449] The method for preparing the compound represented by the general formula (IV) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0450]
[0451] The compound represented by the general formula (IVA) or its salt undergoes a deprotection reaction under acidic conditions to obtain the compound represented by the general formula (IV) or its pharmaceutically acceptable salt;
[0452] Among them, R W is an amino protecting group; preferably PMB;
[0453] R 4 is a hydrogen atom;
[0454] Ring C, Q, L, X 2 , X 3 , X 4 , G 1 , G 2 , G 3 , R 1 , R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in general formula (IV).
[0455] Plan 10
[0456] The method for preparing the compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0457]
[0458] The compound represented by the general formula (VA) or its salt undergoes a deprotection reaction under acidic conditions to obtain the compound represented by the general formula (V) or its pharmaceutically acceptable salt;
[0459] Among them, R W is an amino protecting group; preferably PMB;
[0460] R 4 is a hydrogen atom;
[0461] Ring B, Ring C, Q, L, R8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in formula (V).
[0462] Plan 10-1
[0463] The method for preparing the compound represented by the general formula (V-1) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0464] The compound represented by the general formula (V-1A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (V-1) or a pharmaceutically acceptable salt thereof;
[0465] Among them, R W is an amino protecting group; preferably PMB;
[0466] R 4 is a hydrogen atom;
[0467] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in the general formula (V-1).
[0468] Plan 10-2
[0469] The method for preparing the compound represented by the general formula (V-2) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0470]
[0471] The compound represented by the general formula (V-2A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (V-2) or a pharmaceutically acceptable salt thereof;
[0472] Among them, R W is an amino protecting group; preferably PMB;
[0473] R 4is a hydrogen atom;
[0474] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in the general formula (V-2).
[0475] Plan 10-3
[0476] The method for preparing the compound represented by the general formula (V-3) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps: The compound represented by the general formula (V-3A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (V-3) or a pharmaceutically acceptable salt thereof;
[0477] Among them, R W is an amino protecting group; preferably PMB;
[0478] R 4 is a hydrogen atom;
[0479] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in general formula (V-3).
[0480] Plan 10-4
[0481] The method for preparing the compound represented by the general formula (V-4) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0482] The compound represented by the general formula (V-4A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound represented by the general formula (V-4) or a pharmaceutically acceptable salt thereof;
[0483] Among them, R W is an amino protecting group; preferably PMB;
[0484] R 4 is a hydrogen atom;
[0485] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 , R 2 '、R 3 , R 5 , R 6 , R 7 , R 9 and t are as defined in the general formula (V-4).
[0486] Plan 10-5
[0487] The present invention discloses a method for preparing the compounds represented by the general formula (V-1), (V-2), (V-3) and (V-4) or their pharmaceutically acceptable salts, comprising the following steps:
[0488]
[0489] The compound represented by the general formula (V) or its salt is subjected to chiral resolution to obtain the compound represented by the general formula (V-1), (V-2), (V-3) and (V-4) or its pharmaceutically acceptable salt;
[0490] in,
[0491] Ring B, Ring C, Q, L, R 8a , R 8b , R 8c , R 01 ,s,R 2 '、R 2 To R 7 , R 9 and t are as defined in formula (V-1), (V-2), (V-3) or (V-4).
[0492] The reagents providing acidic conditions in the above scheme include but are not limited to hydrogen chloride, a 1,4-dioxane solution of hydrogen chloride, a 1,4-dioxane solution of hydrochloric acid, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, concentrated sulfuric acid, methanesulfonic acid, nitric acid, phosphoric acid, p-toluenesulfonic acid, Me3SiCl and TMSOTf; preferably trifluoroacetic acid.
[0493] The reaction in the above steps is preferably carried out in a solvent, and the solvent used includes but is not limited to: pyridine, ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-hexane, dimethyl sulfoxide, 1,4-dioxane, water, N,N-dimethylformamide, N,N-dimethylacetamide, 1,2-dibromoethane and mixtures thereof. DETAILED DESCRIPTION
[0494] The following embodiments are used to further describe the present disclosure, but these embodiments are not intended to limit the scope of the present disclosure.
[0495] Example
[0496] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10 -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 nuclear magnetic spectrometer or a Bruker AVANCE NEO 500M, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) as the measurement solvent, and tetramethylsilane (TMS) as the internal standard.
[0497] MS was measured using Agilent 1200 / 1290 DAD-6110 / 6120 Quadrupole MS liquid spectrometer-mass spectrometer (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS).
[0498] waters ACQuity UPLC-QD / SQD (Manufacturer: waters, MS model: waters ACQuity QdaDetector / waters SQ Detector)
[0499] THERMO Ultimate 3000-Q Exactive (Manufacturer: THERMO, MS model: THERMOQExactive)
[0500] High performance liquid chromatography (HPLC) analysis was performed using Agilent HPLC 1200DAD, Agilent HPLC 1200VWD and Waters HPLC e2695-2489.
[0501] Chiral HPLC analysis was performed using an Agilent 1260DAD high performance liquid chromatograph.
[0502] High performance liquid chromatography was performed using Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP and Gilson GX-281 preparative chromatographs.
[0503] Chiral preparations were performed using a Shimadzu LC-20AP preparative chromatograph.
[0504] The CombiFlash rapid preparation instrument used was Combiflash Rf200 (TELEDYNE ISCO).
[0505] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) adopts a specification of 0.15mm-0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm.
[0506] Silica gel column chromatography generally uses Yantai Huanghai Silica Gel 200-300 mesh silica gel as the carrier.
[0507] Average kinase inhibition rate and IC 50 The values were determined using NovoStar microplate reader (BMG, Germany).
[0508] The known starting materials disclosed herein can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, AccelaChemBio Inc, Darui Chemicals, Shanghai Leyan, Shanghai Bid, and other companies.
[0509] Unless otherwise specified in the examples, all reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.
[0510] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1L.
[0511] Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
[0512] The pressurized hydrogenation reaction uses a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or a HC2-SS hydrogenator.
[0513] The hydrogenation reaction is usually carried out by evacuating the vacuum, filling with hydrogen, and repeating the operation three times.
[0514] The microwave reaction was carried out using a CEM Discover-S 908860 microwave reactor.
[0515] Unless otherwise specified in the examples, the solution refers to an aqueous solution.
[0516] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.
[0517] The reaction progress in the embodiment is monitored by thin layer chromatography (TLC), the developing solvent used in the reaction, the eluent system of column chromatography used for purifying the compound and the developing solvent system of thin layer chromatography include: A: dichloromethane / methanol system, B: n-hexane / ethyl acetate system, C: petroleum ether / ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.
[0518] Example 1
[0519] 1-(5-((5-fluoro-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidine
[0520] -3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea 1
[0521]
[0522] first step
[0523] 2-Bromo-4-fluoro-1-(methoxymethoxy)benzene 1b
[0524] 2-Bromo-4-fluorophenol 1a (10.6 g, 55.5 mmol, Shanghai Shaoyuan) was dissolved in dichloromethane (300 mL), N,N-diisopropylethylamine (8.6 g, 66.56 mmol) was added, and then bromomethyl methyl ether (7.3 g, 58.77 mmol) was added, and the mixture was stirred for 14 hours, and saturated sodium bicarbonate aqueous solution was added to quench, and the mixture was extracted with dichloromethane (100 mL×3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution system C to obtain the title compound 1b (12.76 g, yield: 97.8%). MS m / z (ESI): 234.2 [M+1].
[0525] Step 2
[0526] Ethyl 2-(5-fluoro-2-(methoxymethoxy)phenyl)-2-oxoacetate 1c
[0527] Compound 1b (12.5 g, 53.18 mmol) was dissolved in tetrahydrofuran (160 mL), and a 2.5 M solution of n-butyl lithium in tetrahydrofuran (23.4 mL) was added dropwise at -78°C. The temperature was maintained and the mixture was stirred for 1 hour. Diethyl oxalate (15.55 g, 106.4 mmol) was added. After stirring for 1 hour, saturated aqueous ammonium chloride solution was added to quench the mixture. The mixture was extracted with ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution system C to give the title compound 1c (11.7 g, yield: 85.8%).
[0528] MS m / z(ESI):257.2[M+1].
[0529] Step 3
[0530] Ethyl 2-(5-fluoro-2-(methoxymethoxy)phenyl)acrylate 1d
[0531] Methyltriphenylphosphonium bromide (3.1 g, 9.14 mmol, Shanghai Leyan) and potassium tert-butoxide (1 g, 8.91 mmol) were mixed in toluene (100 mL), heated to 105°C and stirred for 3 hours, cooled to room temperature, compound 1c (1.5 g, 5.85 mmol) was added, stirred for 14 hours, quenched by adding saturated aqueous ammonium chloride solution, extracted with ethyl acetate (50 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution system C to obtain the title compound 1d (1.1 g, yield: 73.9%). MS m / z (ESI): 255.2 [M+1].
[0532] Step 4
[0533] Ethyl 1-(5-fluoro-2-(methoxymethoxy)phenyl)cyclopropane-1-carboxylate 1e
[0534] Trimethyl sulfoxide iodide (8.18 g, 37.17 mmol, Shanghai Shaoyuan) was dissolved in dimethyl sulfoxide (90 mL), sodium hydride (1.27 g, 31.86 mmol, 60% purity) was added, and the reaction was stirred for 1 hour. A solution of compound 1d (5.4 g, 21.24 mmol) in dimethyl sulfoxide (15 mL) was added, and the reaction was stirred for 14 hours. A saturated aqueous solution of ammonium chloride was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed three times with water, and then dried over anhydrous sodium sulfate. The desiccant was filtered out and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution system C to obtain the title compound 1e (4.81 g, yield: 84.4%).
[0535] MS m / z(ESI):269.2[M+1].
[0536] Step 5
[0537] (1-(5-Fluoro-2-(methoxymethoxy)phenyl)cyclopropyl)methanol 1f
[0538] Compound 1e (4.7 g, 17.52 mmol) was dissolved in tetrahydrofuran (100 mL), 1 M lithium aluminum hydroxide solution in tetrahydrofuran (21 mL) was added at 0°C, the reaction was stirred for 1 hour, 0.8 mL of water and 0.8 mL of 15% aqueous sodium hydroxide solution were added to quench, the mixture was filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution system C to give the title compound 1f (3.98 g, yield: 100%).
[0539] MS m / z(ESI):227.2[M+1].
[0540] Step 6
[0541] 2-(1-(Bromomethyl)cyclopropyl)-4-fluoro-1-(methoxymethoxy)benzene 1g
[0542] Compound 1f (3.4 g, 15.03 mmol) was dissolved in dichloromethane (50 mL), triphenylphosphine (4.73 g, 18.03 mmol) was added at 0°C, carbon tetrabromide (5.98 g, 18.03 mmol) was added in batches, and after stirring for 2 hours, saturated sodium bicarbonate aqueous solution was added to quench, and the mixture was extracted with dichloromethane (50 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution system C to obtain the title compound 1g (4.1 g, yield: 94.3%)
[0543] MS m / z(ESI):289.2[M+1].
[0544] Step 7
[0545] 2-(1-(Bromomethyl)cyclopropyl)-4-fluorophenol 1h
[0546] Compound 1g (4.1 g, 14.18 mmol) was dissolved in dichloromethane (30 mL), trifluoroacetic acid (7 mL) was added, and the reaction was stirred for 5 hours. The reaction solution was concentrated under reduced pressure, and the pH was adjusted to pH>7 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with dichloromethane (50 mL×3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure to obtain the crude title compound 1h (3.53 g), which was directly used in the next step without purification.
[0547] MS m / z(ESI):244.9[M+1].
[0548] Step 8
[0549] 5-Fluoro-2H-spiro[benzofuran-3,1'-cyclopropane]1i
[0550] The crude compound 1h (3.53 g, 14.40 mmol) was dissolved in acetonitrile (50 mL), cesium carbonate (7 g, 21.48 mmol) was added, and the mixture was reacted at 80°C for 14 hours. The reaction solution was cooled to room temperature and then filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography with elution system C to obtain the title compound 1i (1.28 g, yield: 54.1%).
[0551] MS m / z(ESI):165.1[M+1].
[0552] Step 9
[0553] 5-Fluoro-7-nitro-2H-spiro[benzofuran-3,1'-cyclopropane]1j
[0554] Compound 1i (1.04 g, 6.33 mmol) was dissolved in acetic anhydride (15 mL), and a solution of nitric acid (579 mg, 6.34 mmol, 409.8 μL, purity 69%) in acetic anhydride (2 mL) was added dropwise at 0°C. The reaction was stirred for 30 minutes, and water was added and stirred for 15 minutes. The mixture was extracted with ethyl acetate (25 mL×3). The organic phases were combined, washed with saturated aqueous sodium bicarbonate solution and saturated sodium chloride solution, and then dried over anhydrous sodium sulfate. The desiccant was filtered out and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution system C to give the title compound 1j (525 mg, yield: 39.6%).
[0555] MS m / z(ESI):210.2[M+1].
[0556] Step 10
[0557] 5-Fluoro-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine 1k
[0558] Compound 1j (525 mg, 2.51 mmol), iron powder (560 mg, 10.03 mmol), ammonium chloride (1.08 g, 20.19 mmol) were mixed in water (5 mL) and ethanol (20 mL), and stirred at 85°C for 6 hours. The reaction solution was cooled to room temperature and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent C to obtain the title compound 1k (366 mg, yield: 81.3%)
[0559] MS m / z(ESI):180.2[M+1].
[0560] Step 11
[0561] N 5 -(5-Fluoro-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)-N 7 -(4-methoxybenzyl)-N 7 -Methyl-3-nitropyrazolo[1,5-a]pyrimidine-5,7-diamine1l
[0562] 5-Chloro-N-(4-methoxybenzyl)-N-methyl-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (450 mg, 1.3 mmol, prepared by the method disclosed in Example 1 on page 48 of the specification of the patent application "US2021139486"), compound 1k (252 mg, 1.4 mmol) were dissolved in 1,4-dioxane (10 mL), palladium acetate (29 mg, 129 μmol), 2,2'-bis(diphenylphosphine)-1,1'-binaphthyl (80 mg, 128.5 μmol), cesium carbonate (843 mg, 2.6 mmol) were added, and the mixture was stirred at 120 ° C for 1 hour in a microwave. The reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. Dichloromethane was added to the residue for slurrying, filtered, and the filter cake was dried to obtain the crude title compound 1l (458 mg), which was directly used in the next reaction without purification.
[0563] MS m / z(ESI):491.2[M+1].
[0564] Step 12
[0565] N 5 -(5-Fluoro-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)-N 7 -(4-methoxybenzyl)-N 7 -Methylpyrazolo
[0566] [1,5-a]pyrimidine-3,5,7-triamine 1m
[0567] The crude compound 1l (458 mg, 933.8 μmol) was dissolved in N-methylpyrrolidone (10 mL) and water (2 mL), and iron powder (521 mg, 9.3 mmol) and ammonium chloride (500 mg, 9.3 mmol) were added. The reaction was stirred at 90°C for 3 hours. The reaction solution was cooled to room temperature and then filtered. The filter cake was washed with N-methylpyrrolidone, and water was added to the filtrate, which was filtered. The filter cake was washed with water and dried to obtain the crude title compound 1m (366 mg), which was directly used in the next step without purification.
[0568] MS m / z(ESI):461.2[M+1].
[0569] Step 13
[0570] 1-(5-((5-fluoro-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)amino)-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea 1n
[0571] Phenyl ((1R,2S)-2-fluorocyclopropyl)carbamate (186 mg, 953 μmol, prepared by the method disclosed in Example 3 on page 49 of the specification of the patent application "US2021139486"), crude compound 1m (366 mg, 794.8 μmol) was dissolved in N,N-dimethylformamide (10 mL), triethylamine (160 mg, 1.6 mmol) was added, and the mixture was heated to 80°C for 2.5 hours. After the reaction solution was cooled to room temperature, water was added, filtered, and the filter cake was washed with water and dried to obtain the crude title compound 1n (490 mg), which was directly used in the next step without purification. MS m / z (ESI): 562.2 [M+1].
[0572] Step 14
[0573] 1-(5-((5-fluoro-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea 1
[0574] The crude compound 1n (490 mg, 872.5 μmol) was dissolved in dichloromethane (15 mL), trifluoroacetic acid (4 mL) and anisole (0.5 mL) were added, and the reaction was stirred for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by high performance liquid preparative chromatography (Waters-2545, chromatographic column: YMC Triart-Exrs C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30 mL / min) to give the title compound 1 (250 mg, yield: 64.9%).
[0575] MS m / z(ESI):442.1[M+1].
[0576] 1H NMR (500MHz, DMSO-d6): δ8.51(s,1H),8.24(dd,1H),8.00(s,1H),7.74(s,1H),7.54(t,1H),6.61(d,1H),6.31(dd,1H ),5.89(s,1H),4.78-4.63(m,1H),4.58(s,2H),2.87(d,3H),2.66-2.61(m,1H),1.08-1.01(m,5H),0.85-0.77(m,1H).
[0577] Example 2
[0578] 1-(5-((7-fluoro-3H-spiro[benzo[b][1,4]dioxin-2,1'-cyclopropane]-5-yl)amino)-7-(methylamino)pyrazolo[4-(4-(2-((7-fluoro-3H-spiro[benzo[b][1,4]dioxin-2,1'-cyclopropane]-5-yl)amino)-7-(methylamino)pyrazolo[4-(2-(((7-fluoro
[0579] [1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea
[0580]
[0581] first step
[0582] Tert-butyl(1-((2,4-difluoro-6-nitrophenoxy)methyl)cyclopropyloxy)dimethylsilane 2c
[0583] (1-((tert-butyldimethylsilyl)oxy)cyclopropyl)methanol 2a (1.4 g, 6.9 mmol, prepared by the method disclosed in the literature "Heterocycles, 1990, vol.31, #7, p.1237-1240") was dissolved in N,N-dimethylformamide (50 mL), sodium hydride (415 mg, 10.4 mmol, purity 60%) was added at 0°C, the temperature was maintained and stirred for 1 hour, 1,2,5-trifluoro-3-nitrobenzene 2b (1.22 g, 6.9 mmol, Shanghai Bid) in N,N-dimethylformamide (20 mL) was added dropwise at -40°C, the reaction was naturally restored to room temperature and stirred for 16 hours, saturated ammonium chloride solution was added to the reaction solution to quench, and the reaction solution was extracted with ethyl acetate (35 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure after removing the desiccant to obtain the crude title compound 2c (2.5 g) was directly used in the next reaction without purification.
[0584] Step 2
[0585] 7-Fluoro-5-nitro-3H-spiro[benzo[b][1,4]dioxin-2,1'-cyclopropane]2d
[0586] The crude compound 2c (7.5 g, 20.9 mmol) was dissolved in tetrahydrofuran (100 mL), and a 1M tetrabutylammonium fluoride solution in tetrahydrofuran (105 mL) was added. The reaction mixture was stirred for 4 hours, and water was added to the reaction solution. The mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure after removing the desiccant. The residue was purified by silica gel column chromatography with eluent system B to obtain the title compound 2d (2.5 g, yield: 53%).
[0587] Step 3
[0588] 7-Fluoro-3H-spiro[benzo[b][1,4]dioxin-2,1'-cyclopropane]-5-amine 2e
[0589] Compound 2d (500 mg, 2.22 mmol) was dissolved in methanol (30 mL), palladium carbon hydrogenation catalyst (wet) (120 mg) was added, hydrogen was replaced, and the reaction was stirred for 1 hour. The reaction solution was filtered and the filtrate was concentrated under reduced pressure to obtain the crude title compound 2e (430 mg), which was directly used in the next step without purification.
[0590] MS m / z(ESI):196.2[M+1].
[0591] Step 4
[0592] 1-(5-((7-fluoro-3H-spiro[benzo[b][1,4]dioxin-2,1'-cyclopropane]-5-yl)amino)-7-(methylamino)pyrazolo[4-(4-(2-((7-fluoro-3H-spiro[benzo[b][1,4]dioxin-2,1'-cyclopropane]-5-yl)amino)-7-(methylamino)pyrazolo[4-(2-(((7-fluoro
[0593] [1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea
[0594] The synthetic route from step 11 to step 14 in Example 1 was followed, and the starting compound 1k in step 11 was replaced by compound 2e to obtain the title compound 2 (60 mg, yield: 42%).
[0595] MS m / z(ESI):458.2[M+1].
[0596] 1H NMR(500 MHz, DMSO-d6): δ8.38(s,1H),8.22-8.19(m,1H),8.02(s,1H),7.78(s,1H),7.58-7.55(m,1H),6.65-6.55(m,1H),6.33-6.30(m,1H),5.9 6(s,1H),4.79-4.63(m,1H),4.29(s,2H),2.89-2.88(m,3H),2.65-2.61(m,1H),1.05-1.03(m,2H),0.91-0.89(m,2H),0.85-0.77(m,2H).
[0597] Example 3
[0598] 1-(5-((6-fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutane[e][1,4]dioxin-4-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea (cis isomer mixture) 3
[0599]
[0600] first step
[0601] 2-(Benzyloxy)cyclobutane-1-one 3b
[0602] 1,2-Bis(trimethylsilyloxy)cyclobutene 3a (100 g, 433.9 mmol, Jiangsu Aikon) and benzyl alcohol (46.9 g, 433.9 mmol) were mixed in a 4M hydrogen chloride solution in 1,4-dioxane (300 mL), and reacted at 80° C. for 4 hours. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography with eluent system C to give the title compound 3b (43.8 g, yield: 57.3%).
[0603] Step 2
[0604] 2-(Benzyloxy)cyclobutane-1-ol 3c
[0605] Compound 3b (20.4 g, 115.8 mmol) was dissolved in tetrahydrofuran (200 mL), nitrogen was replaced three times, and the mixture was cooled to -78°C. A 1M solution of lithium tri-sec-butylborohydride in tetrahydrofuran (127.3 mL) was added dropwise. The temperature was maintained and stirred for 1 hour. The mixture was then naturally restored to room temperature and stirred for another hour. The reaction solution was cooled to 0°C, and water (30 mL), 2M aqueous sodium hydroxide solution (30 mL), and hydrogen peroxide (30 mL) were added in sequence. After stirring for 10 minutes, a saturated sodium sulfite solution was added, and the mixture was extracted with ethyl acetate (150 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution system C to obtain the title compound 3c (cis racemate, 18 g, yield: 87.2%).
[0606] Step 3
[0607] 2-(2-(Benzyloxy)cyclobutyloxy)-1,5-difluoro-3-nitrobenzene 3d
[0608] Compound 3c (18.1 g, 101.5 mmol) was dissolved in N,N-dimethylformamide (250 mL), sodium hydride (6.1 g, 152.5 mmol, purity 60%) was added at 0°C, the temperature was maintained and stirred for 1 hour, a solution of 2,3,5-trifluoronitrobenzene (18 g, 101.5 mmol, Shanghai Bid) in N,N-dimethylformamide (60 mL) was added dropwise at -40°C, the temperature was naturally restored to room temperature and stirred for 1 hour, saturated ammonium chloride solution was added to the reaction solution for quenching, and the reaction solution was extracted with ethyl acetate (150 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure after removing the desiccant, and the residue was purified by silica gel column chromatography with elution system C to obtain the title compound 3d (cis racemate, 27.9 g, yield: 81.9%).
[0609] Step 4
[0610] 2-(2,4-Difluoro-6-nitrophenoxy)cyclobutane-1-ol 3e
[0611] 2-(2,4-Difluoro-6-nitrophenoxy) 2,2,2-trifluoroacetic acid cyclobutyl ester 3f
[0612] Compound 3d (27.9 g, 83.2 mmol) was dissolved in trifluoroacetic acid (100 mL), heated to 80°C for 12 hours, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in dichloromethane (100 mL), washed with saturated sodium bicarbonate solution and saturated sodium chloride solution in sequence. The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with elution system C to obtain a mixture of the title compounds 3e and 3f (cis racemate, 28 g).
[0613] Step 5
[0614] 6-Fluoro-4-nitro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutane[e][1,4]dioxin 3g
[0615] A mixture of compounds 3e and 3f (28 g) and cesium carbonate (40 g, 123 mmol) were added to N,N-dimethylformamide (200 mL), heated to 120°C, and stirred for 1 hour. The reaction solution was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography with eluent C to obtain the title compound 3g (cis racemate, 14.5 g).
[0616] Step 6
[0617] 6-Fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutane[e][1,4]dioxin-4-amine 3h
[0618] Compound 3g (14.5 g, 64.4 mmol) was dissolved in tetrahydrofuran (100 mL) and methanol (20 mL), 10% palladium carbon hydrogenation catalyst (wet) (4 g) was added, hydrogen was replaced, the reaction was stirred for 16 hours, the reaction solution was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system B to give the title compound 3h (cis racemate, 10.5 g, yield: 83.5%).
[0619] MS m / z(ESI):196.2[M+1].
[0620] Step 7
[0621] N 5 -(6-Fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutane[e][1,4]dioxin-4-yl)-N 7 -(4-methoxybenzyl)-N 7 -Methyl-3-nitropyrazolo[1,5-a]pyrimidine-5,7-diamine 3i
[0622] 5-Chloro-N-(4-methoxybenzyl)-N-methyl-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (750 mg, 2.15 mmol) and compound 3h (443 mg, 2.26 mmol) were dissolved in 1,4-dioxane (20 mL), and palladium acetate (97 mg, 432 μmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (270 mg, 432 μmol), cesium carbonate (1.4 g, 4 .3mmol), stirred at 100℃ for 3 hours, the reaction solution was cooled to room temperature, filtered, the filtrate was concentrated under reduced pressure, water was added to the residue, extracted with dichloromethane (20mL×3), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered to remove the desiccant and concentrated under reduced pressure, the residue was slurried with a small amount of ethyl acetate, filtered, and the filter cake was dried to obtain the crude title compound 3i (cis racemate, 450mg), which was directly used in the next step without purification.
[0623] MS m / z(ESI):507.2[M+1].
[0624] Step 8
[0625] N 5 -(6-Fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutane[e][1,4]dioxin-4-yl)-N 7 -(4-methoxybenzyl)-N 7 -Methylpyrazolo[1,5-a]pyrimidine-3,5,7-triamine 3j
[0626] The crude compound 3i (450 mg, 888.5 μmol) was dissolved in ethanol (10 mL) and water (3 mL), and iron powder (200 mg, 3.6 mmol) and ammonium chloride (381 mg, 7.1 mmol) were added. The mixture was stirred at 80°C for 4 hours. The reaction solution was cooled to room temperature and diluted with water. The mixture was extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give the title compound 3j (cis racemate, 380 mg, yield: 89.7%). MS m / z (ESI): 477.2 [M+1].
[0627] Step 9
[0628] 1-(5-((6-fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutano[e][1,4]dioxin-4-yl)amino)-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea 3k
[0629] Phenyl ((1R,2S)-2-fluorocyclopropyl)carbamate (99 mg, 50.7 μmol) and compound 3j (200 mg, 419.7 μmol) were dissolved in N,N-dimethylformamide (5 mL), and N,N-diisopropylethylamine (163 mg, 1.26 mmol) was added. The mixture was heated to 80°C for 2.5 hours. After the reaction solution was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure to obtain the crude title compound 3k (cis isomer mixture, 242 mg), which was directly used in the next step without purification.
[0630] MS m / z(ESI):578.2[M+1].
[0631] Step 10
[0632] 1-(5-((6-fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutane[e][1,4]dioxin-4-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea 3
[0633] The crude compound 3k (200 mg, 346.2 μmol) was dissolved in dichloromethane (10 mL), trifluoroacetic acid (4 mL) was added, and the reaction was stirred for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by high performance liquid preparative chromatography (Waters-2545, chromatographic column: YMC Triart-Exrs C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30 mL / min) to obtain the title compound 3 (cis isomer mixture, 50 mg, yield: 31.5%).
[0634] MS m / z(ESI):458.2[M+1].
[0635] 1 H NMR (500MHz, DMSO-d6): δ8.38(s,1H),8.22-8.19(m,1H),8.02(s,1H),7.78(s,1H),7.58-7.55(m,1H),6.66-6.65(m,1H),6.33-6.30( m,1H),5.96(s,1H),4.82-4.76(m,2H),2.90-2.89(m,3H),2.65-2.61(m,1H),2.21-2.05(m,4H),1.28-1.21(m,1H),1.07-0.77(m,2H).
[0636] Example 3-p1, 3-p2
[0637] 1-(5-(((2aR,8aS)-6-fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutano[e][1,4]dioxin-4-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea 3-p1
[0638] 1-(5-(((2aS,8aR)-6-fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutano[e][1,4]dioxin-4-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea 3-p2
[0639]
[0640] The compound of Example 3 (600 mg) was separated by chiral column (Shimadzu LC-20AP, chromatographic column: CHIRALPAKIG, 20*250 mm, 5 μm; mobile phase A: n-hexane, mobile phase B: ethanol (containing 0.5% di-7M ammonia methanol solution), gradient ratio: A: B is 50:50, flow rate: 20 mL / min) to obtain the title compound 3-p1 (260 mg, yield: 43.3%), 3-p2 (260 mg, yield: 43.3%).
[0641] MS m / z (ESI): 458.2 [M+1]. Single configuration compound (short retention time) 3-p1 (260 mg, yield: 43.3%)
[0642] MS m / z(ESI):458.2[M+1].
[0643] Chiral HPLC analysis: retention time 11.486 minutes, purity: 99% (chromatographic column: CHIRALPAK IG, 5μm, 4.6*150mm; mobile phase: A: n-hexane, mobile phase B: ethanol (containing 0.1% diethylamine), gradient ratio: A: B is 50:50, flow rate: 1mL / min).
[0644] 1H NMR (500MHz, DMSO-d6): δ8.38(s,1H),8.22-8.19(m,1H),8.02(s,1H),7.78(s,1H),7.58-7.55(m,1H),6.66-6.65(m,1H),6.33-6.30( m,1H),5.96(s,1H),4.82-4.76(m,2H),2.90-2.89(m,3H),2.65-2.61(m,1H),2.21-2.05(m,4H),1.28-1.21(m,1H),1.07-0.77(m,2H).
[0645] Single configuration compound (longer retention time) 3-p2 (260 mg, yield: 43.3%)
[0646] MS m / z(ESI):458.2[M+1].
[0647] Chiral HPLC analysis: retention time 17.911 minutes, purity: 99% (chromatographic column: CHIRALPAK IG, 5μm, 4.6*150mm; mobile phase: A: n-hexane, mobile phase B: ethanol (containing 0.1% diethylamine), gradient ratio: A: B is 50:50, flow rate: 1mL / min).
[0648] 1 H NMR (500MHz, DMSO-d6): δ8.38(s,1H),8.22-8.19(m,1H),8.02(s,1H),7.78(s,1H),7.58-7.55(m,1H),6.66-6.65(m,1H),6.33-6.30( m,1H),5.96(s,1H),4.82-4.76(m,2H),2.90-2.89(m,3H),2.65-2.61(m,1H),2.21-2.05(m,4H),1.28-1.21(m,1H),1.07-0.77(m,2H).
[0649] Example 4
[0650] 1-Cyclobutyl-3-(5-((6-fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutano[e][1,4]dioxin-4-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)urea
[0651]
[0652] first step
[0653] 1-Cyclobutyl-3-(5-((6-fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutane[e][1,4]dioxin-4-yl)amino
[0654] 4a
[0655] Compound 3j (100 mg, 209.8 μmol) and N,N-diisopropylethylamine (135.6 mg, 1.05 mmol) were mixed in dichloromethane (10 mL). Triphosgene (62.2 mg, 209.8 μmol) was added under ice bath. After the temperature was maintained for 0.5 hour, cyclobutylamine (71.1 mg, 22.4 μmol, Shanghai Shaoyuan) was added. The temperature was maintained for 1 hour with stirring. Methanol was added to the reaction solution for quenching and the solution was concentrated under reduced pressure to obtain the crude title compound 4a (mixture of cis isomers, 120 mg). The solution was used directly in the next step without purification.
[0656] MS m / z(ESI):574.2[M+1].
[0657] Step 2
[0658] 1-Cyclobutyl-3-(5-((6-fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutano[e][1,4]dioxin-4-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)urea
[0659] The crude compound 4a (120 mg, 209.2 μmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added, and the reaction was stirred for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by high performance liquid preparative chromatography (Waters-2545, chromatographic column: YMC Triart-Exrs C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 30%-42%, flow rate: 30 mL / min) to obtain the title compound 4 (cis isomer mixture, 31 mg, yield: 32.6%).
[0660] MS m / z(ESI):454.2[M+1]. 1H NMR (500MHz, CDCl3): δ7.95(s,1H),7.90-7.87(dd,1H),7.08(s,1H),6.38(dd,1H),6.21-6.20(m,1H),6.02(s,1H),5.45-5.41(m,2 H),4.75-4.70(m,2H),4.34-4.26(m,1H),3.10(d,3H),2.37-2.31(m,2H),2.25-2.19(m,4H),1.85-1.77(m,2H),1.71-1.64(m,2H).
[0661] Example 5
[0662] 1-Cyclopropyl-3-(5-((6-fluoro-1,2,2a,8a-tetrahydrobenzo[b]cyclobutane[e][1,4]dioxin-4-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)urea
[0663]
[0664] The synthetic route of Example 4 was adopted, and the first step raw material cyclobutylamine was replaced by cyclopropylamine (Shanghai Shaoyuan) to obtain the title compound 5 (cis isomer mixture, 32.5 mg, yield: 25.8%).
[0665] MS m / z(ESI):440.2[M+1].
[0666] 1 H NMR(500 MHz, CDCl3): δ8.22(s,1H),8.13-8.01(m,1H),7.21-7.09(m,1H),6.99-6.81(m,1H),6.38(dd,1H),6.21(s,1H),5.34(s,1H),5 .22-5.13(m,1H),4.75-4.71(m,2H),3.09(d,3H),2.70-2.68(m,1H),2.26-2.24(m,4H),0.90-0.89(m,2H),0.74-0.67(m,2H).
[0667] Biological evaluation
[0668] Test Example 1: TYK2 JH2 in vitro enzyme binding assay
[0669] This experiment uses the fluorescence resonance energy transfer (TR-FRET) method to test the inhibitory effect of compounds on TYK2 JH2 and JAK1JH2 pseudokinases. In this experiment, TYK2 JH2 or JAK1 JH2 pseudokinases can be combined with Tracer with fluorescent labels and Tb antibodies at the same time. Tb antibodies, as fluorescence donors, produce 495nm wavelength fluorescence under the action of a certain wavelength of excitation light, while Tracer, as a fluorescence receptor, can only receive 495nm wavelength fluorescence when it is close enough to Tb antibodies to produce 520nm wavelength fluorescence, that is, fluorescence resonance energy transfer signals. When compounds are added to compete with Tracer for binding to the pseudokinase JH2 region, the TR-FRET signal is weakened due to the reduction of Tracer binding. The 520nm / 495nm signal ratio can reflect the strength of the inhibitory activity of the compound binding to the pseudokinase.
[0670] 1. Experimental reagents and instruments
[0671]
[0672] Micropipette instrument: Echo (LABCYTE Echo550)
[0673] ·Microplate reader: Envision2105 (Perkin Elmer)
[0674] Constant temperature incubator: CIMO, SPX-60BS-II
[0675] Thermo MATRIX multichannel pipette: Thermo Fisher, 2-125μL
[0676] Centrifuge: Thermo Centrifuge ST 40R
[0677] · Water Purifier: Millipore Milli-Q Reference System
[0678] Ultra-low temperature freezer: Haier ultralow temperature freezer
[0679] ·Refrigerator: Haier 4degree freezer; Haier-20degree freezer
[0680] 2. Experimental Methods
[0681] 2.1. Prepare 1× experimental working solution
[0682] Ingredients Final concentration (mM) HEPES pH 7.5 20 <![CDATA[MgCl2]]> 10 Brij-35 0.015% DTT 2 BSA 50 μg / mL
[0683] 2.2. The experimental operation is as follows:
[0684] 2.2.1. Dissolve compounds in DMSO to a stock concentration of 10 mM.
[0685] 2.2.2. Prepare compound dilution plates with different concentration gradients of compounds 200 times the final concentration and transfer them to Echo plates.
[0686] 2.2.3. Transfer 75 nL of compound from the Echo plate to the 384 assay plate using the Echo instrument.
[0687] 2.2.4. Add 5 μL of TYK2 JH2 and JAK1 JH2 pseudokinases at 3 times the final concentration (0.5 nM) to a 384-well assay plate and centrifuge at 1000 rpm for 30 seconds.
[0688] 2.2.5. Add 5 μL of Tb antibody at 3 times the final concentration (1× is the final concentration) to each well of a 384-well assay plate and centrifuge at 1000 rpm for 30 seconds.
[0689] 2.2.6. Add 5 μL of Tracer at 3 times the final concentration (final concentration: 1 nM for TYK2 JH2, 30 nM for JAK1 JH2) to each well of a 384-well assay plate and centrifuge at 1000 rpm for 30 seconds.
[0690] 2.2.7. Incubate at room temperature for 60 minutes or at 4°C overnight.
[0691] 2.2.8. The 520 nm / 495 nm fluorescence signal ratio was read using Envision microplate reader (PerkinElmer).
[0692] 3. Data Analysis
[0693] The test data was processed and analyzed using XLfit, a software developed by IDBS and integrated into the Microsoft Excel environment. First, the average reaction signals of the high signal control wells and the low signal control wells were calculated respectively, and then the reaction inhibition rate of each compound well was calculated according to the formula "single well inhibition rate % = 100-(high signal control group average value-single well signal value) / (high signal control group average value-low signal control group average value)". Then the concentration and corresponding inhibition rate data were imported into the XLfit software, and the Dose Response One Site 205 model in the software was used to fit the inhibition rate-concentration curve using the four-parameter method, and the IC of the compound was calculated. 50 value.
[0694] Table 1 IC values of TYK2 JH2 and JAK1 JH2 pseudokinase binding inhibitory activities 50
[0695]
[0696] Conclusion: The disclosed compounds have obvious selective inhibitory effects on TYK2-JH2 pseudokinase.
[0697] Test Example 2: Inhibition experiment of the disclosed compounds on IFNα-induced STAT1 protein phosphorylation in HeLa cells
[0698] The AlphaLISA method was used to detect the inhibitory effect of the disclosed compounds on IFNα-induced STAT1 protein phosphorylation in HeLa cells, and the specific contents are as follows:
[0699] 1.1 Reagents and instruments
[0700] 1.1.1 Reagents
[0701]
[0702] 1.1.2 Instruments
[0703] Instrument Name factory Model Information Automatic cell counter Countstar IC1000 Hood Thermo 1300AII Thermo Incubator Thermo I160 PHERASTAR HS Microplate Reader BMG LABTECH PHERASTAR HS Centrifuge Beckman Coulter Allegra X-12centrifuge
[0704] 1.2 Cells and culture methods
[0705] HeLa cells were purchased from the American Type Culture Collection (ATCC) and cultured in MEM medium (10% FBS) at 37° C. in a 5% carbon dioxide incubator, and passaged 2-3 times a week.
[0706] 1.3 Compound preparation
[0707] a. Test compounds were dissolved in DMSO to 0.5 mM.
[0708] b. The initial concentration of the compound was 0.5 mM, 3-fold dilution, and 10 concentration gradients.
[0709] c. Dilute all concentration compounds 50 times with culture medium and set aside.
[0710] 4. Experimental Procedure
[0711] a. Count the cells and adjust the cell density to 5×10 with fresh culture medium. 5 / mL.
[0712] b. 96 black polystyrene microplate, inoculate 80 μL of cells per well and culture at 37°C for 4 hours.
[0713] c. Add 10 μL of compound to each well (10 μL of 0.5% DMSO to columns 1 and 12) and incubate at 37°C for 1 hour.
[0714] d. Prepare 100 ng / mL IFNα with culture medium, add 10 μL IFNα to each well (add 10 μL culture medium to the first column as a control), and culture at 37°C for 15 minutes.
[0715] e. Prepare lysis solution according to the instructions of AlphaLISA SureFire Ultra STAT1 pY701 kit. Aspirate the cell culture supernatant, add 50 μL lysis solution to each well, and shake at room temperature for 15 minutes.
[0716] f. Prepare Acceptor Mix according to the instructions of the AlphaLISA SureFire Ultra STAT1 pY701 kit. Add 5 μL of Acceptor Mix to each well of a 96-well low-display white plate.
[0717] g. Transfer 10 μL of cell lysate to a 96-well low-display white plate, centrifuge, and incubate at room temperature for 1 hour.
[0718] h. Prepare Donor Mix according to the instructions of AlphaLISA SureFire Ultra STAT1 pY701 Kit. Protect from light, add 5 μL Donor Mix to each well, and incubate at room temperature overnight.
[0719] i. Read the plate using PHERASTAR HS Microplate reader.
[0720] j. Graphpad software was used to draw graphs and calculate the IC of the disclosed compounds 50 value.
[0721] Table 2 Inhibitory activity of the disclosed compounds on IFNα-induced STAT1 protein phosphorylation in HeLa cells
[0722] Compound No. <![CDATA[IC 50 (nM)]]> 3-p1 28.8 3-p2 26.1
[0723] Conclusion: The disclosed compounds have a good inhibitory effect on IFNα-induced STAT1 protein phosphorylation in HeLa cells.
[0724] In addition, the disclosed compounds have weak inhibitory activity on IL2-induced pSTAT5 phosphorylation in human PBMC cells (IC 50 40μM), with good selectivity.
[0725] The disclosed compounds have good inhibitory activity (IC 50 <500nM), and has good inhibitory activity on IL-12-induced IFN-γ production in human PBMC cells (IC 50<500nM), and has a strong inhibitory effect on TYK2-mediated and IFNα-induced STAT3 phosphorylation in human T lymphocytes (IC 50 <100nM).
Claims
1. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof: in: R 0 Selected from X 1 , X 2 , X 3 and X 4 One of them is a carbon atom and is connected to NR 7 connected, the rest are the same or different and are each independently N or CR 8 ; R A , R B and the carbon atoms connected thereto form a polycyclic cycloalkyl, a polycyclic heterocyclic group, a polycyclic aryl or a polycyclic heteroaryl; the polycyclic cycloalkyl, polycyclic heterocyclic group, polycyclic aryl and polycyclic heteroaryl are each independently and optionally substituted by one or more R 9 replaced by; Q and L are the same or different and are each independently selected from a bond, O, (CR g R h ) p 、O(CR g R h ) p , (CR g R h ) p O、NR i 、C(O)NR i NR i C(O) and S(O) q ; Ring Cy is a cycloalkyl group or a heterocyclyl group; Ring C is a cycloalkyl group or a heterocyclyl group; G 1 Selected from N, NR 10 and CR'; G 2 N or C; G 3 N or C; G 4 is N or CR"; R 1 is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, and The alkyl, alkoxy, cycloalkylalkyl and heterocyclylalkyl groups are each independently optionally substituted with one or more R 01 replaced by; Ring B is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; R 2 , R 2 '、R 4 , R 5 , R 7 , R 10 and R i are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, a cycloalkyl group and a heterocyclic group; the alkyl group, the alkoxy group, the cycloalkyl group and the heterocyclic group are each independently optionally replaced by one or more R 02 replaced by; R 3 , R 6 , R' and R" are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a NR 20 R 21 、C(O)NR 20 R 21 、Alkylene NR 20 R 21 、Alkylene C(O)NR 20 R 21 NR 22 C(O)R 23 NR 22 C(O)NR 20 R 21 、C(O)R 23 、C(O)OR 23 、OC(O)R 23 、OC(O)OR 23 、S(O) r R 23 、S(O) r OR 23 、OS(O) r R 23 、S(O) r NR 20 R 21 NR 22 S(O) r R 23 、C(=NR 22 )R 23 、C(=NR 22 )NR 20 R 21 、S(=NR 22 )(O)R 23 、P(O)R 23 R 24 , OR 23 , cycloalkyl, heterocyclic, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R 03 replaced by; Each R 8 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a NR 20 R 21 、C(O)NR 20 R 21 、Alkylene NR 20 R 21 、Alkylene C(O)NR 20 R 21 NR 22 C(O)R 23 NR 22 C(O)NR 20 R 21 、C(O)R 23 、C(O)OR 23 、OC(O)R 23 、OC(O)OR 23 、S(O) r R 23 、S(O) r OR 23 、OS(O) r R 23 、S(O) r NR 20 R 21 NR 22 S(O) r R 23 、C(=NR 22 )R 23 、C(=NR 22 )NR 20 R 21 、S(=NR 22 )(O)R 23 、P(O)R 23 R 24 , OR 23 , cycloalkyl, heterocyclic, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R 03 replaced by; Each R e , R f , R g and R h are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a NR 20 R 21 , OR 23 , cycloalkyl, heterocyclic, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R 03 or R e , R f Together they form =O, or R g , R h Together they form = O; Each R 9 , R 01 , R 02 and R 03 are the same or different and are each independently selected from a deuterium atom, an oxo group, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a deuterated alkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an alkenyl group, an alkynyl group, ═CR 23 R 24 NR 20 R 21 、C(O)NR 20 R 21 、Alkylene NR 20 R 21 、Alkylene C(O)NR 20 R 21 NR 22 C(O)R 23 NR 22 C(O)NR 20 R 21 、C(O)R 23 、C(O)OR 23 、OC(O)R 23 、OC(O)OR 23 、S(O) r R 23 、S(O) r OR 23 、OS(O) r R 23 、S(O) r NR 20 R 21 NR 22 S(O) r R 23 、C(=NR 22 )R 23 、C(=NR 22 )NR 20 R 21 、S(=NR 22 )(O)R 23 、P(O)R 23 R 24 , OR 23 , nitro, cycloalkyl, heterocyclyl, cycloalkyloxy, heterocyclyloxy, aryl, heteroaryl, aryloxy and heteroaryloxy; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, cycloalkyloxy, heterocyclyloxy, aryl, heteroaryl, aryloxy and heteroaryloxy groups are each independently substituted with one or more R*; Each R 20 , R 21 , R 22 , R 23 and R 24 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, a hydroxyl group, an alkenyl group, an alkynyl group, NR a R b 、C(O)NR a R b 、Alkylene NR a R b 、Alkylene C(O)NR a R b NR c C(O)R d NR c C(O)NR a R b 、C(O)R d 、C(O)OR d 、OC(O)R d 、OC(O)OR d , OR d , cycloalkyl, heterocyclyl, aryl and heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently substituted by one or more R*; or R 20 , R 21 and the nitrogen atom to which it is attached together form a heterocyclic group, which is optionally substituted by one or more R*; Each R a , R b , R c and R d are the same or different and are each independently selected from alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkenyl, alkynyl, amino, NHCH 3 、N(CH 3 ) 2 , amide, C(O)NHCH 3 、C(O)N(CH 3 ) 2 , acetyl, alkyleneamino, alkyleneamido, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy, heterocyclyloxy, aryl and heteroaryl; or, R a , R b and the nitrogen atom to which it is attached together form a heterocyclic group, wherein the heterocyclic group is substituted by one or more R*; Each R* is the same or different and is independently selected from a deuterium atom, an oxo group, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an alkenyl group, an alkynyl group, an amino group, NHCH 3 、N(CH 3 ) 2 , amide, C(O)NHCH 3 、C(O)N(CH 3 ) 2 , acetyl, alkyleneamino, alkyleneamido, nitro, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy, heterocyclyloxy, aryl, and heteroaryl; Each r and q are the same or different and are each independently 0, 1 or 2; m is 0, 1, 2, 3, 4, 5 or 6; t is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, or 6; and, p is 0, 1, 2, 3, 4, 5 or 6.
2. The compound represented by the general formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in: R 0 Selected from v is 0, 1, 2, 3, or 4, R 8b For R 8 , R 8 As defined in claim 1.
3. The compound represented by the general formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, which is a compound represented by the general formula (III), or a pharmaceutically acceptable salt thereof: in, U selected from CR 1a R 1b , O, S(O) r and NR 1c ; R 01a is a hydrogen atom or R 01 ; R 1a and R 1b are the same or different and are each independently a hydrogen atom or R 01 ; The condition is that R 1a and R 1b When one of them is an oxo group, the other one does not exist; R 1c is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, and a heterocyclic group; R 8a , R 8b and R 8c The same or different, and each independently is R 8 ; u is 0, 1, 2, 3, 4, or 5; Cy, Q, L, R 01 , r, R 2 '、R 2 To R 9 , m and t are as defined in claim 1.
4. The compound represented by the general formula (I) according to claim 1 or 3, or a pharmaceutically acceptable salt thereof, in: Ring Cy is a 3- to 6-membered cycloalkyl group; preferably, ring Cy is a cyclopropyl group.
5. A compound represented by general formula (I) according to any one of claims 1, 3 and 4, or a pharmaceutically acceptable salt thereof, in: Q is O, and / or L is a bond or O.
6. A compound represented by general formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, in: R 4 is a hydrogen atom, and R 5 C 1-6 alkyl.
7. The compound represented by the general formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, which is selected from any one of the following compounds:
8. A compound represented by the general formula (IA) or a salt thereof: in, R W is an amino protecting group, preferably PMB; G 1 , G 2 , G 3 , G 4 , R 0 To R 3 , R 2 '、R 5 , R 6 and R 7 As defined in claim 1.
9. A compound or a salt thereof, which is selected from any of the following structures:
10. A method for preparing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising: include: The compound represented by the general formula (IA) or its salt undergoes a deprotection reaction to obtain the compound represented by the general formula (I) or its pharmaceutically acceptable salt; Among them, R W is an amino protecting group, preferably PMB; R 4 is a hydrogen atom; G 1 , G 2 , G 3 , G 4 , R 0 To R 3 , R 2 '、R 5 , R 6 and R 7 As defined in claim 1.
11. A pharmaceutical composition comprising a compound represented by general formula (I) according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
12. Use of the compound represented by general formula (I) according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 11 in the preparation of a TYK2 inhibitor.
13. Use of a compound of formula (I) according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 11 in the preparation of a medicament for treating and / or preventing a disease or condition mediated by or dependent on TYK2.
14. Use of a compound of formula (I) according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 11 in the preparation of a medicament for treating and / or preventing proliferative diseases, metabolic diseases, allergic diseases, inflammatory diseases and autoimmune diseases; preferably, the inflammatory disease or autoimmune disease is selected from arthritis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus erythematosus, inflammatory bowel disease, psoriasis, psoriatic arthritis, intestinal disease, Crohn's disease, Sjögren's syndrome, systemic scleroderma, ulcerative colitis, Graves' disease, discoid lupus erythematosus, adult Still's disease, juvenile idiopathic arthritis, gout, gouty arthritis, sepsis, septic shock, shigellosis, pancreatitis, glomerulonephritis, spontaneous nephritis, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, vitiligo, atopic dermatitis, myasthenia gravis , ankylosing spondylitis, pemphigus vulgaris, Goodpasture's syndrome, antiphospholipid syndrome, idiopathic thrombocytopenia, ANCA-associated small vessel vasculitis, pemphigus, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy, dermatomyositis, polymyositis, uveitis, Guillain-Barré syndrome, autoimmune pneumonia, autoimmune thyroiditis, autoimmune inflammatory eye disease, chronic demyelinating polyneuropathy, alopecia areata and hidradenitis suppurativa; more preferably, the inflammatory disease or auto The immune disease is selected from rheumatoid arthritis, dermatitis, psoriasis or inflammatory bowel disease; the metabolic disease is preferably diabetes; the proliferative disease is preferably cancer; the cancer is preferably selected from breast cancer, cervical cancer, colorectal cancer, lung cancer, gastric cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, peritoneal tumors, melanoma, glioma, neuroblastoma, head and neck cancer, leukemia, lymphoma and myeloma.
